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ABSTRACT
Identification of Structural Changes Associated with Regulation of Tyrosine
Hydroxylase. (August 2010)
Shanzhi Wang, B.S., Jilin  University
Co-Chairs of Advisory Committee: Dr. Paul F. Fitzpatrick
                                                             Dr. Gregory D. Reinhart
Tyrosine hydroxylase (TyrH) is the first and rate-limiting enzyme of
catecholamine synthetic pathway, and its regulation is critical for controlling
catecholamine synthesis. The well recognized regulatory mechanisms are inhibition by
catecholamine binding and re-activation upon Ser40 phosphorylation. Catecholamines
bind to TyrH tightly, while phosphorylation of TyrH at Ser40 decreases the binding
affinity by several hundred-fold. Regulation of TyrH is accompanied by conformational
changes of the protein. This study focuses on the identification of the conformational
changes of TyrH upon dopamine binding and Ser40 phosphorylation, using hydrogen
deuterium exchange mass spectrometry (HDMS) and fluorescence spectroscopy.
HDMS identifies three peptides undergoing conformational changes upon
dopamine binding, peptide 35-41, 42-71 and 295-299. Peptides 35-41 and 42-71 are on
the regulatory domain, while peptide 295-299 is at the active site entrance.  Upon
dopamine binding, all three peptides are protected from exchange; phosphorylation of
TyrH at Ser40 has opposite effects on the exchange kinetics of peptide 295-299, but
peptides 35-41 and 42-71 could not be detected by MS after phosphorylation.  This
iv
suggests that the structural effects of dopamine binding and Ser40 phosphorylation are
opposite.
The fluorescence spectroscopy of mutant enzymes containing a single tryptophan
at position 14, 34 or 74 was performed before and after phosphorylation. F34W/F3W
TyrH has a significant decrease in steady-state fluorescence anisotropy, an increase in
the bimolecular quenching rate constant kq and dynamic anisotropy upon
phosphorylation at Ser40, while F14W/F3W TyrH and F74W/F3W TyrH exhibit much
smaller differences. This suggests that phosphorylation of TyrH at Ser40 increases the
flexibility of the regulatory domain.
The results are consistent with TyrH existing in two conformations, a closed
conformation stabilized by dopamine in which the N-terminal regulator domain of TyrH
covers the active site entrance and an open conformation stabilized by phosphorylation
in which the regulatory domain has moved away from the active site entrance.
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ABBREVIATIONS
TyrH Tyrosine hydroxylase
DOPA Dihydroxyphenylalanine
PheH Phenylalanine hydroxylase
TrpH Tryptophan hydroxylase
BH4 Tetrahydrobiopterin
PKA Protein kinase A
ACT Aspartate kinase – chorismate mutase – TyrA
CvPheH PheH from Chromobacterium violaceum
KSV Stern-Volmer quenching constant
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1CHAPTER I
INTRODUCTION
CATECHOLAMINE SYTHETIC PATHWAY
Catecholamines are neurotransmitters released from the sympathetic nervous
system. They are also called “fight and flight” hormones, because they are largely
released in response to stress. The name catecholamine comes from the common
chemical composition, a catechol group and an amine group. Because they serve as
neurotransmitters, the disturbance of their homeostasis can lead to disease. The
overproduction of catecholamines can result in hypertension (1) due to their sympathetic
stimulation, while decreased production of them, especially dopamine, can cause central
nervous system problems, e.g., Parkinson’s disease (2) and DOPA-responsive dystonia
(Segawa’s disease) (3). Dopamine, nonepinephrine and epinephrine are the most
abundant catecholamines; others are synthesized using them as backbones.
As shown in Figure 1.1, the synthesis of catecholamines starts from tyrosine. In
this step, tyrosine hydroxylase (TyrH) catalyzes the hydroxylation of the aromatic ring
of tyrosine to form dihydroxyphenylalanine (DOPA), using molecular oxygen and
tetrahydrobiopterin (4, 5). This step is the rate-limiting step in the catecholamine
synthetic pathway and is subject to regulation (4). The following step is decarboxylation
of DOPA to form dopamine; this step is catalyzed by the enzyme DOPA decarboxylase
using cofactor pyridoxal phosphate (6). Next, the production of nonepinephrine is
_____________
This dissertation follows the style of Biochemistry.
2catalyzed by the enzyme dopamine β-hydroxylase using molecular oxygen and ascorbic
acid (6). Finally, the enzyme phenylethanolamine N-methyltransferase catalyzes the
conversion of norepinephrine into epinephrine, using S-adenosyl-methionine (6).
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Figure 1.1: Catecholamine biosynthetic pathway.
3Catecholamines can be degraded either by catechol-O-methyltransferases
(COMT) (7) or by monoamine oxidases (MAO) (8). COMT transfers a methyl group to
one of the hydroxyl groups on the catechol, while MAO oxidizes the amine group to
form an aldehyde group.
AROMATIC AMINO ACID HYDROXYLASE FAMILY
 TyrH is found in the central nervous system and adrenal medulla. It belongs to
the small family of aromatic amino acid hydroxylases, which also includes
phenylalanine hydroxylase (PheH) and tryptophan hydroxylase (TrpH).  PheH is a liver
enzyme that catalyzes the catabolism of excess phenylalanine into tyrosine, the first step
of phenylalanine degradation. A deficiency of this enzyme can lead to phenylalanine
accumulation in the body and contributes to most of the cases of phenylketonuria (9).
TrpH is found in the gastrointestinal tract and central nervous systems. It catalyzes the
first step in the biosynthesis of serotonin, the formation of 5-hydroxytryptophan from
tryptophan (10); a deficiency of this enzyme can lead to  depression (11). As shown in
Figure 1.2, the hydroxylation of all three aromatic amino acids requires molecular
oxygen and tetrahydrobiopterin. In addition, a non-heme ferrous iron is required at the
active site for catalysis (12-14). All three enzymes are composed of an N-terminal
regulatory domain, a catalytic domain and a tetramerization domain at the very C-
terminus(15-20). The rat forms of the enzymes share a sequence identity of ~50% in the
catalytic domains, but less than 15% sequence identity in the regulatory domains (Figure
1.3). It is generally accepted that they share a common chemical mechanism (21), but
have distinct regulatory mechanisms (5).
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Figure 1.2: The reactions catalyzed by aromatic amino acid hydroxylases.
5TyrH  MPTPSAPSPQPKGFRRAVSEQDAKQAEAVTSPRFIGRRQSLIEDARKEREAAAAAAAAAV 60
PheH  --------------MAAVVLENGVLSRKLSD---FGQETSYIEDNSNQN----------- 32
TrpH  ------------------MIED-------------NKEN---KDHSSER----------- 15
                          ::             .:.    :*  .:.           
TyrH  ASSEPGNPLEAVVFEERDGNAVLNLLFSLRGTKPSSLSRAVKVFETFEAKIHHLETRPAQ 120
PheH  --------------------GAISLIFSLK-EEVGALAKVLRLFEENDINLTHIESRPSR 71
TrpH  --------------------GRVTLIFSLK-NEVGGLIKALKIFQENHVNLLHIESRKSK 54
                          . :.*:***:  : ..* :.:::*:  . :: *:*:* ::
   
TyrH  RPLAGSPHLEYFVRFEVPSGDLAALLSSVRRVSDDVRSARED----------KVPWFPRK 170
PheH  L---NKDEYEFFTYLDKRSKPV--LGSIIKSLRNDIGATVHELSRDKE--KNTVPWFPRT 124
TrpH  R---RNSEFEIFVDCDINREQLNDIFPLLKSHTTVLSVDSPDQLPEKEDVMETVPWFPKK 111
           . . * *.  :     :  : . ::     :     :          .*****:.
TyrH  VSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYKHGEPIPHVEYTAEEI 230
PheH  IQELDRFANQILSYGAELDADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYTEEEK 184
TrpH  ISDLDFCANRVLLYGSELDADHPGFKDNVYRRRRKYFAELAMNYKHGDPIPKIEFTEEEI 171
      :.:**   : :  :..:** *****.* *** *** :*::* :*:**:***::*:* **
TyrH  ATWKEVYVTLKGLYATHACREHLEGFQLLERYCGYREDSIPQLEDVSRFLKERTGFQLRP 290
PheH  QTWGTVFRTLKALYKTHACYEHNHIFPLLEKYCGFREDNIPQLEDVSQFLQTCTGFRLRP 244
TrpH  KTWGTIFRELNKLYPTHACREYLRNLPLLSKYCGYREDNVPQLEDVSNFLKERTGFSIRP 231
       **  ::  *: ** **** *: . : **.:***:***.:*******.**:  *** :**
TyrH  VAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQ 350
PheH  VAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQ 304
TrpH  VAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPLYTPEPDTCHELLGHVPLLAEPSFAQFSQ 291
      *** **.****..******:****:**.*.*:::**** *********:::: :******
TyrH  DIGLASLGASDEEIEKLSTVYWFTVEFGLCKQNGELKAYGAGLLSSYGELLHSLSEEPEV 410
PheH  EIGLASLGAPDEYIEKLATIYWFTVEFGLCKEGDSIKAYGAGLLSSFGELQYCLSDKPKL 364
TrpH  EIGLASLGASEETVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELRHALSGHAKV 351
      :********.:* ::**:* *:*********:...::.:******* .** :.** ..::
TyrH  RAFDPDTAAVQPYQDQTYQPVYFVSESFNDAKDKLRNYASRIQRPFSVKFDPYTLAIDVL 470
PheH  LPLELEKIACQEYSVTEFQPLYYVAESFSDAKEKVRTFAATIPRPFSVRYDPYTQRVEVL 424
TrpH  KPFDPKVACKQECLITSFQDVYFVSESFEDAKEKMREFAKTVKRPFGVKYNPYTQSIQVL 411
       .:: .  . *      :* :*:*:***.***:*:* :*  : ***.*:::***  ::**
TyrH  DSPHTIQRSLEGVQDELHTLAHALSAIS----- 498
PheH  DNTQQLKILADSINSEVGILCNALQKIK----- 452
TrpH  RDSKSITSAMNELRHDLDVVNDALARVSRWPSV 444
       ..: :    : :. ::  : .**  :.
Figure 1.3: Sequence alignment of rat TyrH, PheH and TrpH. The default parameters of
Clustal W2 were used. Conserved residues are indicated using *, and the start of the
catalytic domain is indicated by a solid triangle.
6STRUCTURES OF THE AROMATIC AMINO ACID HYDROXYLASES
There are several structures available for various forms of the three enzymes,
with most structures of PheH. As expected, the catalytic domains have very high
structurally similarity (Figure 1.4). The active site is a 10 Å deep and 17 Å wide cleft
containing a non-heme iron atom chelated by two conserved histidines and one
conserved glutamate (13, 14, 22).  In rat TyrH, His331 and His336 were identified as
iron-chelating residues by mutagenesis studies before the crystal structure became
available (23), while the corresponding residues in rat PheH, His285 and His290, were
also identified prior to the crystal structure (24). Although the third iron-chelating
residue was not directly identified by mutagenesis studies, its presence as a carboxylic
amino acid had been predicted (21). This facial triad motif is used by a variety of non-
heme iron binding enzymes (25); unlike other enzymes with the same motif, the
substrates of the three aromatic amino acid hydroxylases do not directly coordinate to
the iron. The C-terminal 45 residues contain a long α-helix at the very end and two short
β-sheets. The β-sheets of two adjacent subunits form hydrogen bonds, while the α-
helices of four subunits form a coiled-coil tetramer (13, 14).  The coiled-coil structure
had been predicted based on its sequence and mutagenesis studies (26, 27). Mutations of
the coiled-coil of TyrH dissociate the tetramer into dimers (27), while additional deletion
of the N-terminal regulatory domain yields monomers (26).
7Figure 1.4: Structures of the catalytic domains of TyrH (1TOH), PheH (2PHM) and
TrpH (1MLW).
8A structure of the regulatory domain is only available for PheH, although the
first eighteen residues are missing from the structure (28). The protein is a dimer due to
the deletion of the C-terminal 25 residues. In contrast, structures of PheH lacking the
regulatory domain appear to be tetramers. As shown in Figure 1.5, the structure of the
“intact” PheH can be re-constructed from these structures, by aligning the catalytic
domains. Residues 20-30 form a flexible loop extending over the top of the active site,
while the rest of the regulatory domain forms an ACT domain (29) with a typical
βαββαβ structure (28). When the tetrameric structure of PheH is viewed as two dimers,
each ACT domain interacts with both catalytic domains in the dimer. Thus, the ACT
domains may play a role in maintaining the quaternary structure of PheH.
Figure 1.5: The re-constructed structure of PheH. The structure of PheH was built using
PDB files 2PAH and 2PHM. The regulatory domain is in red and the rest of the protein
in gray.
9PheH is the only aromatic amino acid hydroxylase, for which structures with
both amino acid and pterin bound are available (30). Although not a natural substrate,
the amino acid β-thienylalanine has been shown to be able to bind PheH and trigger BH4
oxidization (31). Thus, the structures of PheH with both BH4 and β-thienylalanine bound
can provide significant insight into the substrate binding sites as well as catalysis. As
shown in Figure 1.6, BH4 and β-thienylalanine are separated from each other in the
tertiary structure in two different binding pockets. This suggests that there is not a direct
chemistry between the two substrates during catalysis, ruling out the hydroxylating
intermediate being a pterin derivative. The N(3)-N(5) side of BH4 faces the iron, and
Glu286 is the only amino acid to interact with BH4 on this side. The importance of
Glu286 for BH4 binding has been demonstrated by mutagenesis. Mutating Glu286 of
PheH to alanine increases the Km value of the pterin by 70-fold (32); mutating the
corresponding residue in TyrH, Glu332, to alanine increases the Km value by 10 fold
(33). BH4 also interacts with Phe254 by π stacking; mutating the corresponding residue
Phe300 to alanine in TyrH decreases the rate constant for pterin oxidization by 5 fold
(34). The N(1)-N(8) side of BH4 is hydrogen-bonded with residues Gly247 to Ser251 of
a loop. N(8) and the amino group at C(2) of BH4 are hydrogen-bonded to the backbone
carbonyl groups of Leu249 and Gly247, while the side chain at C(6) of BH4 interacts
with the hydroxyl side chain of Ser251. Many 6-substibuted tetrahydropterins can serve
as substrates (5) of the aromatic amino acid hydroxylases and Ser251 is not a conserved
residue in the family, suggesting the interaction with Ser251 is not critical for BH4
binding.
10
Figure 1.6: BH4 (A) and amino acid (B) binding sites of PheH (1KW0).  A: β-
thienylalanine is colored yellow. B: BH4 is colored yellow.
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The amino group of β-thienylalanine interacts with the side chain of Thr278,
and the carboxylate group interacts with the amide nitrogen of Thr278, the side chain of
Arg270, and the side chain Ser349 (Figure 1.6). The side chain of Arg 270 forms two
hydrogen bonds with the carboxylate group of β-thienylalanine; mutating this residue in
TyrH to Lys decreases the kcat/Km value for the amino acid substrate by 4700 fold (33).
The side chain of the amino acid substrate is held in a hydrophobic pocket consisting of
the side chains of Tyr138, Pro281, Trp326 and Phe331.
Deletion of the regulatory domains of the aromatic amino acid hydroxylases
yield proteins with the same substrate preferences as the intact proteins (17, 35, 36),
indicating that all the residues determining the substrate specificity are in the catalytic
domains. In light of the high sequence identity, similar structures of the catalytic
domains and the similar chemical reactions, the substrate specificities of the aromatic
amino acid hydroxylases are likely to be due to small differences in the hydrophobic
pocket of the amino acid binding site. Trp326 of PheH is also a tryptophan residue in
TyrH, but it is a phenylalanine residue in TrpH; the other three residues of the
hydrophobic pocket are more conserved. The bulky side chain of Trp326 of PheH (or
TyrH) is a candidate for discriminating phenylalanine (or tyrosine) from tryptophan as a
substrate. Mutating the tryptophan to a phenylalanine in PheH yields a protein preferring
tryptophan as a substrate to phenylalanine by 30-fold (37). However, mutating the
corresponding phenylalanine to tryptophan in TrpH yields an enzyme with a similar
preference for phenylalanine or tryptophan (37), and the same mutation in TyrH does not
cause a change of substrate preference (38), indicating that the discrimination for
12
tryptophan as a substrate is not totally dependent on whether phenylalanine or
tryptophan is at this position. This also suggests that residues outside of the hydrophobic
pocket are also involved in substrate specificity in TyrH. Most of the non-conserved
residues in the second sphere of the active site are in loops. There are four loops at the
entrance of the active site in PheH (also in TyrH and TrpH), 131-147, 244-251, 270-282
and 375-343.  Loop 244-251 packs against the pterin far away from the amino acid
binding site and this loop is well conserved (except residue 251 at the very end). Thus, it
is unlikely to be related to amino acid specificity. The residues of the other three loops
(especially the center residues) are not conserved across the aromatic amino acid
hydroxylase family, but are well conserved for each aromatic amino acid hydroxylase.
Loop 131-147 undergoes a dramatic conformational change when both pterin and amino
acid are bound to PheH; the center residue of the loop, Tyr138, moves more than 10 Å
from the surface of the protein into the active site. The corresponding loop in TyrH, 177-
193, is also critical for catalysis (39). Mutations switching the center residues of this
loop in TyrH and PheH did not alter the substrate specificity (39). Swapping of the
center residue of loop 270-282 or/and 375-343 of PheH with the corresponding residue
in TyrH causes dramatic effects on substrate preference. H264Q/V379D PheH has a
decrease in preference for phenylalanine versus tyrosine as a substrate by 3000-fold (40),
although phenylalanine is still preferred over tyrosine. In contrast, D425V TyrH
(corresponding to V379D  PheH) and Q310H TyrH (corresponds to H264Q PheH) have
a preference of tyrosine to phenylalanine as a substrate (40), with the former having a
8000-fold preference of phenylalanine to tyrosine and the latter having 35-fold. These
13
results indicate that the packing of second sphere residues shapes the substrate-binding
pocket and contributes to the substrate specificity.
MECHANISM
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Figure 1.7: Proposed chemical mechanism of TyrH (21).
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Tyrosine hydroxylase is the best mechanistically characterized enzyme in the
aromatic amino acid hydroxylase family (21, 41), and the proposed mechanism is shown
in Figure 1.7.  Catalysis only occurs after all the substrates are bound. The binding of
substrates is ordered. Pterin binds first, followed by molecular oxygen and then tyrosine
(41).
The oxygen atom of the 4a-hydroxy pterin product comes from molecular
oxygen (42), suggesting there is a direct reaction between molecular oxygen and BH4.
The presence of a peroxy-pterin intermediate has been proposed based on the results of
tetrahydropterin autoxidation, in which quinonoid dihydropterin and H2O2 are formed as
products. The formation of a peroxypterin intermediate is also suggested in the enzyme-
catalyzed reaction, in that when tyrosine is used as a substrate for PheH, the
hydroxylation of tyrosine is slow while the consumption of tetrahydropterin is much
faster and yields H2O2 (43). The formation of the hydroxylating intermediate has been
suggested to be the first irreversible step based on an 18O kinetic isotope effect of 1.0175
on kcat/KO2 (44). The peroxypterin cannot serve as the direct hydroxylating intermediate,
because this would require breakage of the peroxy O-O bond and hydroxylation of the
amino acid in a concerted step. As a result, the amount of pterin oxidized would always
equal the amount of amino acid hydroxylated. S395A TyrH has ~1% wild-type activity
in terms of formation of DOPA, but this mutant retains the wild-type enzyme activity in
terms of formation of the hydroxypterin (45). Similar to this, using phenylalanine as a
substrate, TyrH consumes pterin faster than tyrosine. These results suggest that the
hydroxylating intermediate is formed after the formation of peroxypterin.
15
Compared with autoxidation of pterin, the enzyme-catalyzed oxidization of
pterin is much faster, suggesting that iron of the active site is facilitating the reaction
between molecular oxygen and pterin. The geometry and electronic structure of the
active site iron have been studied using X-ray absorption spectroscopy (XAS) and
magnetic circular dichroism (MCD).  The iron of resting PAH (ferrous enzyme with no
ligand) is six coordinate (6C), while it becomes five coordinate (5C) after phenylalanine
and pterin binding (46). Thus, the opening of the coordination position is likely to make
room for the reaction with molecular oxygen. The coordination states of the active site
iron of PheH were later supported by the X-ray structure, in which the resting PheH is
coordinated by three water molecules, two histidines and one glutamate; amino acid and
pterin bound PheH is five coordinate due to the lost of two water molecules and the
glutamate switching to bidentate coordination (30, 47).  Similar studies have been
performed on TyrH, although a structure of ferrous TyrH is not available. The structure
of ferric TyrH with or without a dihydrobiopterin bound shows a five coordinate iron,
with two water molecules, two histidines and one glutamate (14), but studies using XAS
show that the ferrous TyrH with or without a BH4 bound is six coordinate (48). MCD
and XAS also show that the iron of the resting TyrH is six coordinate and either tyrosine
binding or pterin binding does not alter the coordination state (49). However, when both
tyrosine and pterin are bound to TyrH, the iron is five coordinate (49). Extended X-ray
absorption fine structure spectroscopy (EXAFS) further confirms that TyrH with both
tyrosine and pterin bound is coordinated by one water molecule, two histidines and one
bidentate glutamate (49), consistent with the crystal structure of PheH (30). The
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coordination change of the active site iron is similar to other non-heme iron oxygenases
and it facilitates the activation of molecular oxygen (50-52).
The coordination of molecular oxygen to the iron and the formation of a
peroxypterin intermediate led to the proposal of a Fe(II)-peroxypterin species as an
intermediate (Figure 1.7); this subsequently forms a Fe(IV)O hydroxylating intermediate
after O-O bond cleavage (42) (Figure 1.7). When H2O2 is used in place of pterin and
oxygen, all three enzymes can hydroxylate phenylalanine into tyrosine (53), further
supporting that the hydroxylating intermediate is only formed after the cleavage of O-O
bond of peroxy-peterin. The hydroxylation of phenylalanine does not occur in the apo-
enzymes, establishing a requirement for iron to form the hydroxylating intermediate
(53). Recently, the presence of a Fe(IV)O intermediate during catalysis of TyrH was
directly detected by rapid freeze-quench Mössbauer spectroscopy, with the spectrum
resembling Fe(IV)O intermediates in other iron-containing non-heme dependent
enzymes (54).
The presence of a high valent Fe(IV)O intermediate suggests electrophilic
hydroxylation of the amino acid. The deuterium kinetic isotope effect on kcat is unity for
TyrH and PheH (55), indicating that this chemical step is not rate-limiting (55).
However, an inverse kinetic isotope effect of kcat (0.93) was observed when 5-
2H-
tryptophan was used as a substrate for TrpH. Similarly, mutants of TyrH (H336E TyrH)
and PheH (V379D PheH and I234D CvPheH) show an inverse deuterium kinetic isotope
effect on kcat (56, 57). The inverse kinetic isotope effect suggests that the hybridization
state of the carbon undergoes an sp2 to sp3 transition upon the addition of oxygen.
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Further support for an electrophilic mechanism came from the partitioning of 4-
substitued phenylalanines as substrates for TyrH (58). The ρ values of
tetrahydrobiopterin and 6-methyltetrahydroptein were around -5 (58), indicating the
formation of a very electron poor intermediate after the reaction with the Fe(IV)O
intermediate. The most consistent explanation for all these results is the formation of a
carbocation upon the reaction of the Fe(IV)O intermediate with the amino acid. This is
followed by a 1,2-hydrogen shift at the site of hydroxylation. This shift had been
observed decades ago using isotopically labeled substrates (59).
The formation and decay rate constants of the Fe(IV)O intermediate are 24 s-1
and 35 s-1 respectively at 5 oC determined by rapid freeze-quench Mössbauer
spectroscopy during the first turnover (54), much faster than kcat (~ 0.9 s
-1) during state-
state catalysis (54). This indicates that chemistry is not the rate-determining step of the
reaction. The viscosity effect on kcat is near unity during steady-state analysis (60),
suggesting the reaction is diffusion-limited. The rapid chemical-quench experiment on
TyrH reveals an initial burst during the first few turnovers, suggesting the rate-limiting
event is after chemistry (60). Thus, the rate-limit step during catalysis of TyrH is product
release.
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REGULATION
TyrH is regulated long-term at the gene-expression level and short-term at the
level of enzyme activity (4, 61).  The latter includes feedback inhibition by
catecholamines and activation by phosphorylation or binding with other proteins (5, 61).
There are four phosphorylation sites on the N-terminal regulatory domain of rat
TyrH, Ser8, Ser19, Ser31 and Ser40 (62, 63). Position 8 is a threonine residue in human
TyrH, and the importance of phosphorylation at this position is still not clear. To date,
all mammalian TyrH from different species contain those four sites, suggesting all four
phosphorylation sites have regulatory importance. PKA phosphorylates Ser40
specifically in vitro (62, 63); in vivo, an increase in the concentration of cAMP leads to
increased phosphorylation at Ser40 (62, 63). Calcium and calmodulin dependent protein
kinase II (CaMKII) phosphorylates Ser19 of TyrH in vitro (64); in vivo, an increase in
the calcium concentration increases the level of Ser19 phosphorylation (65, 66). CaMKII
is not specific to Ser19; it also phosphorylates Ser40 both in purified TyrH (64) and in
vivo (65). The MAP-activated protein kinases ERK 1 and 2 phosphorylate Ser31 of
purified TyrH (63, 66); in vivo, the ERK1/2 activators phorbol esters and nerve growth
factor increase the level of Ser31 phosphorylation. ERK2 can also phosphorylate Ser8,
but much slower than Ser31 (67). Protein phosphatase 2A (PP2A) can dephosphorylate
Ser19, Ser31 and Ser40 (61), while protein phosphatase 2C (PP2C) can dephosphorylate
Ser19 and Ser40 (61).
Phosphorylation does not have direct effects on the catalytic activity in the
absence of other ligands (61, 64, 68-70). Consistent with this, deleting the N-terminal
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regulatory domain of TyrH yields a fully active protein (35), suggesting that
phosphorylation does not directly activate TyrH. Instead, phosphorylation regulates the
enzyme activity by modulating the interaction of TyrH with other ligands.
Phosphorylation of Ser19 or Ser31 has been reported to increase the rate constant for
Ser40 phosphorylation (71-73) and to increase the stability of TyrH (71, 72, 74).  In
addition, phosphorylation of Ser19 of TyrH is required for 14-3-3 protein binding (75).
The binding of 14-3-3 proteins decreases the solvent accessibility of Ser19 and Ser40 of
TyrH, decreasing the rate of dephosphorylation at those positions by phosphatases (72,
76). The function of Ser40 phosphorylation is better understood; it activates TyrH by
decreasing the binding affinity of catecholamines by several hundred-fold (77-79).
The regulation of TyrH by catecholamine binding and Ser40 phosphorylation is
shown in Figure 1.8; the active enzyme, which contains a ferrous iron, catalyzes the
hydroxylation of tyrosine into DOPA. The ferrous enzyme can be oxidized to the ferric
enzyme (80), which is either reduced back to the ferrous form by the substrate BH4 or
bound tightly with a catecholamine. Catecholamines bind to ferric TyrH with affinities
of ~ 1 nM (78), and this tight binding prevents the reduction of TyrH to the ferrous form,
keeping the enzyme in an inactive form. Ser40 phosphorylation increases the
dissociation rate constant for a catecholamine by nearly three orders of magnitude (78,
79), so that the catecholamine can dissociate from the active site, followed by the rapid
reduction to the ferrous form (80, 81).
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EFe(lll) catecholamine
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O2 BH4
EFe(ll) BH4O2tyr
BH4, O2, tyr
DOPA, BH3OH
        Ser40 
phosphorylation
Figure 1.8: Regulatory mechanism of TyrH (78).
Structural changes that accompany regulation of TyrH have been suggested by
the fact that catecholamine-bound TyrH is more stable than the resting TyrH (82), while
Ser40-phosphorylated TyrH has decreased stability (83-85). Studies using limited-
proteolysis showed that dopamine binding causes residues 33-50 to be less susceptible to
trypsin digestion, while Ser40 phosphorylation makes the same region more susceptible
to digestion (86). Consistent with this, binding of dopamine decreases the rate constant
for Ser40 phosphorylation (77). Gel-filtration chromatography showed that dopamine-
bound TyrH has a longer retention time than that of TyrH alone, while Ser40-
phosphorylated TyrH has a slightly shorter retention time (71). These results not only
confirm that the conformational changes occur upon regulation, but also suggest that
opposite conformational changes occur upon dopamine binding and Ser40
phosphorylation. To date, a crystal structure is not available for the regulatory domain of
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TyrH. There are structures available of the catalytic domain of PheH with a
catecholamine bound. This can be used to envision the binding of catecholamines to the
catalytic domain of TyrH. The main interaction between the catalytic domain of PheH
and catecholamines is between the two hydroxyl groups of the catechol and the active
site ferric iron. The amine group protrudes out of the active site without any interaction
with the catalytic domain. This suggests that there are interactions between the amino
group and the regulatory domain of TyrH, and catecholamine binding or Ser40
phosphorylation of TyrH is likely to modulate this interaction to regulate the affinity of
catecholamines.
In contrast to TyrH, the activity of PheH can be modulated by its substrates; the
enzyme is inhibited by pterin and activated by phenylalanine. When an assay of purified
PheH is initiated by adding enzyme, the rate of tyrosine formation is much slower for the
first few minutes (87). Pre-incubating PheH with phenylalanine can eliminate this slow
phase (87), while pre-incubation with BH4 will prolong this phase (87). Thus, BH4 and
phenylalanine shift PheH between an active form and an inactive form. The proposed
regulation of PheH by BH4 and phenylalanine (87) is summarized in Figure 1.9: the
resting enzyme is in an inactive form; the binding of phenylalanine shifts it to an active
form, while BH4 binding prevents PheH from activation.
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tyr, BH3OH
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Figure 1.9: Regulatory mechanism of PheH (87).
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The activity of PheH can also be increased by phosphorylation of the N-terminal
regulatory domain at Ser16. Ser16 of PheH can be phosphorylated either by PKA (88) or
CaMPK (89). The enzyme activity is increased less than three-fold after phosphorylation
(90). More importantly, upon Ser16 phosphorylation, PheH is activated more rapidly
upon phenylalanine binding and requires a lower concentration of phenylalanine for
activation (91, 92), suggesting that Ser16 phosphorylation and phenylalanine binding
activate PheH synergistically. Structures of PheH both before and after phosphorylation
are available and the two structures are identical, with the first eighteen residues missing
in both. This suggests that Ser16 phosphorylation induces only small structural changes
before residue 19 or that proteolysis removed these residues before PheH being
crystallized. Mutating Ser16 to aspartate or glutamate has same effects on PheH as
phosphorylation (90), indicating that the charge is responsible for the effect of
phosphorylation.
The truncation of the N-terminal regulatory domain can also eliminate the slow
phase of tyrosine formation (17, 93), suggesting that the regulatory domain is behaving
as an inhibitory fragment. The crystal structure of PheH with both the regulatory domain
and the catalytic domain should represent the inactive PheH; while the crystal structure
of the PheH without the regulatory domain should represent the active PheH. The
structures of the catalytic domains in the two cases are overlapping, suggesting the
movement of the regulatory domain is responsible for activation by phenylalanine. In the
crystal structure of PheH, part of the N-terminal regulatory domain covers the active site
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cleft, suggesting that the regulation of PheH activity modulates substrate entry to the
active site.
HDMS experiments on PheH in the presence or absence of 5 mM phenylalanine
show that several peptides both in the regulatory domain and the catalytic domain have
increased deuterium incorporation upon phenylalanine binding (94). Most of those
peptides are at the interface of the two domains and the active site entrance; however,
the residues of the regulatory domain covering the active site do not show a change in
deuterium incorporation. The results suggest that a global conformational change of
PheH has occurred upon phenylalanine binding. The parallel experiment using the
catalytic domain of PheH (truncating the first 117 residues) only shows changes in the
peptides in the amino acid binding site. The results do not indicate where the
phenylalanine binds to trigger the conformational changes, but a second binding site for
phenylalanine other than the active site is likely.
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CHAPTER II
IDENTIFICATION OF STRUCTURAL CHANGES ASSOCIATED WITH
REGULATION OF TYROSINE HYDROXYLASE BY
HYDROGEN/DEUTERIUM EXCHANGE MASS SPECTROMETRY*
Tyrosine hydroxylase (TyrH1, E.C. 1.14.16.2) catalyzes the conversion of
tyrosine into dihydroxyphenylalanine (DOPA), the first and rate-limiting step of
catecholamine biosynthesis. TyrH belongs to the small family of aromatic amino acid
hydroxylases, which also includes phenylalanine hydroxylase (PheH) and tryptophan
hydroxylase (TrpH) (5). All three enzymes hydroxylate their respective substrate using
tetrahydrobiopterin and molecular oxygen. Phenylalanine hydroxylase is the first and
rate-limiting enzyme for phenylalanine catabolism, and tryptophan hydroxylase is the
first and rate-limiting enzyme of serotonin biosynthesis. As a result, all three
hydroxylases are subject to regulation. In light of the similar reactions they catalyze and
their high structural similarity (13, 14, 22), they are believed to have the same enzymatic
mechanism (21). The mammalian forms of these hydroxylases are tetramers (18, 95, 96)
containing a regulatory domain (100-150 amino acids) at the N-terminus and a larger
catalytic domain (around 350 amino acids) at the C-terminus (15, 17, 19, 35, 36). The
catalytic domains are homologous (15), while the regulatory domains are distinct (15,
16), probably due to the different regulatory mechanisms.
______________
*Reproduced with permission from Wang, S., Sura, G. R., Dangott, L. J., and
Fitzpatrick, P. F. (2009) Identification by hydrogen/deuterium exchange of structural
changes in tyrosine hydroxylase associated with regulation, Biochemistry 48, 4972-4979.
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TyrH is regulated by feedback inhibition by catecholamines and phosphorylation
of serine residues in the regulatory domain (77, 97). TyrH contains a non-heme iron
atom in the active site cleft that must be in the ferrous form for activity (12). The ferrous
enzyme is readily oxidized to the ferric form (80, 81), and dopamine binds to the ferric
enzyme with a dissociation constant of ~ 1 nM (78, 79).  Phosphorylation of Ser40
activates TyrH by increasing the dissociation constant for dopamine ~ 500 fold (78).
Although the structural basis for the regulatory effect is not known, conformational
changes upon dopamine binding and phosphorylation of TyrH have been suggested.
Limited proteolysis with trypsin showed that dopamine binding protects a region on the
regulatory domain of TyrH, and Ser40 phosphorylation makes this region more
susceptible to trypsin degradation (86). TyrH phosphorylated at Ser40 has a shorter
retention time on gel filtration chromatography compared to TyrH alone, and dopamine-
bound TyrH has a slightly longer retention time (71). Until now the only structures
available for TyrH are the catalytic domain with and without 7, 8-dihydrobiopterin
bound (14, 98). To probe the effects of dopamine binding and phosphorylation on the
structure of TyrH, hydrogen deuterium exchange mass spectrometry was used. The
results are described here.
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EXPERIMENTAL PROCEDURES
Materials. Dopamine and ATP were from Sigma-Aldrich Chemical Co.
(Milwaukee, WI). Porcine stomach pepsin A was from Worthington Biochemical Co.
(Lakewood, NJ). Deuterium oxide (D2O, 99% D) was from Cambridge Isotope
Laboratories (Andover, MA). HPLC grade water was from Mallinckrodt Chemical Inc.
(St, Louis, MO), and HPLC grade acetonitrile was from VWR-International (Darmstadt,
Germany). Formic acid was from Michrom Bioresources Inc. (Auburn, CA). All other
chemicals were of the highest purity commercially available.
Protein purification. The catalytic domain of cAMP dependent protein kinase
(PKA) from beef heart was purified according to Flockhart et al (99). Rat tyrosine
hydroxylase was purified as previously described (33). Phosphorylation of TyrH was
performed as previously described (78) with minor modifications. Approximately 10 ml
of TyrH (20 µM) in 50 mM Hepes, 200 mM KCl, and 10% glycerol, pH 7.3, was
incubated with 50 µM ATP, 6 mM MgSO4, 2 µg/ml PKA at 4 
oC for 1 h. An additional
aliquot of ATP was added to give a concentration of 100 µM, followed by another 1 h
incubation. The degree of phosphorylation was monitored using a MonoQ column as
previously described (78). The phosphorylated TyrH was purified using a Q-Sepharose
column. To ensure that the enzyme contained a stoichiometric amount of ferric ion, an
equimolar amount of Fe (NH4)2 (SO4)2 was added to purified TyrH or phosphorylated
TyrH, followed by Q-Sepharose chromatography. The purified protein was stored in
10% glycerol, 200 mM KCl and 200 mM Hepes (pH 7.3) at a concentration of ~ 0.3 mM
at -80 oC.
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To obtain the TyrH-dopamine complex, dopamine was added to 0.3 mM TyrH in
10% glycerol, 200 mM KCl and 200 mM Hepes (pH 7.3) to a final concentration of 0.5
mM. The binding of dopamine to TyrH was monitored by following the absorbance
increase at 690 nm; the binding reaction was complete after 30 minutes at 4 oC.
Hydrogen/deuterium exchange and mass spectrometry.  The exchange reaction
was initiated by diluting 25 µl of 0.3 mM enzyme with 500 µl of D2O buffer (200 mM
Hepes, pD 7.7) at 25 oC. Over the time course of the experiment, 20 µl aliquots were
taken and quenched with 20 µl of 300 mM H3PO4 in H2O at 4 
oC to lower the pH to 2.4.
The quenched sample was immediately frozen with liquid nitrogen and stored at -80 oC
for less than 24 h. Samples were thawed quickly and pepsin (15 mg/ml) was added to
yield ratios of pepsin to TyrH (w/w) of 0.5, 1 or 2. The first 3 min of the pepsin
digestion was performed on ice and the last 2 min of digestion was performed in the 20
µL HPLC injection loop, which was submerged in ice. The resulting peptides were then
injected onto a Vydac C18 column (2.1 mm × 150 mm) connected to a Thermo Finnigan
HPLC system. Most of the HPLC system was kept at 4 oC, including the injection loop,
the tubing, the C18 column and the solvents.  After a 3 min desalting with 98% solvent A
(0.3% formic acid in H2O, pH 2.4) and 2% solvent B (0.3% formic acid in acetonitrile,
pH* 2.4) at a flow rate of 300 µl/min, a gradient of 10 – 60 % solvent B over 9 min was
applied at a flow rate of 200 µl/min. Most of the peptides were eluted at 15% to 50%
acetonitrile within 6 min. The outflow from the HPLC column was injected directly into
a Thermo Finnigan LCQ DECA XP ion-trap mass spectrometer. Singly, doubly and
triply charged peptides, with m/z values of 400 to 2000, were analyzed.
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 To identify peptides, an independent tandem mass spectrometry (MS/MS)
experiment was performed using the same digestion and elution conditions, except that
H2O instead of D2O was used in the dilution step. Peptide assignment was performed
using the program TurboSEQUEST (Thermo Finnigan, version 3.1).
To obtain fully-deuterated peptides, 10 µl of 0.3 mM TyrH was diluted with 200
µl of 200 mM Hepes buffer (pH 7.3) in H2O and 210 µl of 300 mM H3PO4 in H2O at 4
oC. Pepsin was added to give pepsin to protein ratios (w/w) of 1 or 2. After 5 min on ice,
three 50 µl aliquots were taken out and loaded onto three 500 µl Bio-Spin 6 columns to
isolate the peptic peptides. To remove the pepsin, the columns were centrifuged at 1,000
g for 30 s; the flow through was discarded. To collect the peptides, each column was
washed with 300 µl D2O and centrifuged at 1,000 g for 60 s. The washing was repeated
twice, and all the flow through was combined. The pooled samples were lyophilized.
The resulting peptides were resuspended in 20 µl D2O and heated to 90 
oC for 90 min.
After cooling, 5 µl of 500 mM phosphate buffer in D2O (pD 2.8) was added. Twenty µl
of the peptides was loaded onto the HPLC, and peptide separation and analysis were
performed as described above. Only 21 peptides were found with good spectra,
suggesting that there was peptide loss due to the extra steps to obtain fully deuterated
peptides. Under the experimental conditions, the back-exchange level of the 21 well-
resolved peptides was ~ 35%. As a result, a value of 35% back exchange was used for
the rest of the peptides.
Data analysis. The .raw MS files were processed using the Thermo Finnigan
Xcalibur software. The spectra of individual peptides were transferred to Excel, and
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centroid data were identified using the program HX-Express (100); the program
MagTran (101) was also used for the peptides showing altered exchange behaviors and
gave the same results as HX-Express. The deuterium content of individual peptides was
calculated using Equation 2.1, where Mt is the measured mass of the peptide at time t;
MH is the measured mass of the nondeuterated peptide; MD is the measured mass of the
completely deuterated peptide corrected for back-exchange. The time course for
deuterium incorporation of each peptide was fitted to Equation 2.2 or linearly, where N
is the number of exchangeable amide hydrogens over the time course of the experiment,
and A and B are the numbers of amide hydrogens with exchange rate constants k1 and
k2, respectively.
D% = (Mt – MH)/ (MD – MH) × 100%  (2.1)
Y = N - Ae-k1t - Be-k2t  (2.2)
Six independent experiments were performed for each condition. Due to the
availability of the peptides in different pepsin to protein ratios (w/w), most peptides
could be analyzed for four different experiments; all were analyzed in at least two
independent experiments with the same pepsin to protein ratio (w/w). The results were
well reproducible in independent experiments. The results, including standard deviations
indicated in figures were all calculated from the experiments with the same pepsin to
protein ratio (w/w).
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RESULTS
Identification of peptides. Electrospray mass spectrometry of peptic peptides was
used to analyze the extent of deuterium incorporation from solvent into peptide bonds in
TyrH under different conditions. Pepsin was used to generate the peptides because it is
active at pH 2-3 where back-exchange from the peptide bond to solvent is minimized. In
preliminary experiments, the ratio of pepsin to TyrH was varied from 0.5 to 2
(mass/mass). Some different peptides were generated with the different masses of
pepsin. Combining the peptides generated at ratios of pepsin to TyrH of 0.5, 1, and 2
allowed reproducible detection of peptides covering ~70% of the protein (Figure 2.1).
Most of the residues which were not found in peptide peptides by mass spectrometry
were in three regions of the protein: residues 1-27, 143-174, and 191-209. The remainder
of the protein is well-covered.
  1 MATPSAPSPQ PKGFRRAVSE QDAKQAEAVT SPRFIGRRQS LIEDARKERE AAAAAAAAAV 
 61 ASSEPGNPLE AVVFEERDGN AVLNLLFSLR GTKPSSLSRA VKVFETFEAK IHHLETRPAQ 
   
121 RPLAGSPHLE YFVRFEVPSG DLAALLSSVR RVSDDVRSAR EDKVPWFPRK VSELDKCHHL 
     
181 VTKFDPDLDL DHPGFSDQVY RQRRKLIAEI AFQYKHGEPI PHVEYTAEEI ATWKEVYVTL 
241 KGLYATHACR EHLEGFQLLE RYCGYREDSI PQLEDVSRFL KERTGFQLRP VAGLLSARDF 
301 LASLAFRVFQ CTQYIRHASS PMHSPEPDCC HELLGHVPML ADRTFAQFSQ DIGLASLGAS
361 DEEIEKLSTV YWFTVEFGLC KQNGELKAYG AGLLSSYGEL LHSLSEEPEV RAFDPDTAAV 
   
421 QPYQDQTYQP VYFVSESFND AKDKLRNYAS RIQRPFSVKF DPYTLAIDVL DSPHTIQRSL 
  
481 EGVQDELHTL AHALSAIS
Figure 2.1: Peptic peptides (arrows) of TyrH used in the hydrogen deuterium exchange
mass spectrometry experiments.
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Amide H/D exchange dynamics of the native enzyme. Figure 2.2 shows the
changes in deuterium content of peptides in the catalytic domain at different times of
incubation in D2O; no structure is available for the regulatory domain of TyrH. Figure
2.3 illustrates the three different exchange patterns of peptides. There is a central core
around the active site which shows little exchange over the 1 h time course of the
experiment: residues 226-259, 300-354, 364-377, and 387-393. The two histidines and
one glutamate, which act as iron ligands, are all included in these peptides. Three
peptides (28-34, 35-41, 42-71) of the regulatory domain exhibit rapid and complete
exchange in less than 10 s, suggesting that this portion of the protein is highly mobile.
This region contains two of the phosphorylation sites, Ser 31 and Ser 40. The remainder
of the protein shows time-dependent exchange, consistent with EX2 behavior due to
transient formation of exchange-competent conformations. Residues in the
tetramerization domain, 455-498, show very similar patterns of exchange, suggesting
transient dissociation of individual subunits.
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Figure 2.2: The extent of deuterium incorporation into peptides in the catalytic domain
of TyrH at various times. Residues are color-labeled according to the deuterium content
in the respective peptides. The structure of the backbone of residues 178-199 of TyrH
(1TOH) is from the corresponding residues in PheH (3PAH); the iron is shown as a red
sphere.
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Figure 2.3: Time course of deuterium incorporation into peptides 28-34, 266-273,349-
354 and 467-487 for TyrH alone. The lines were obtained by fitting the data to equation
2.2.
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A similar analysis was carried with TyrH lacking the regulatory domain, Δ155
TyrH. Almost 80% of this protein could be detected in the mass spectrometer. While
there were some differences in the identities of the individual peptides, the overall
pattern of exchange was very similar to that seen in the intact protein (results not
shown).
Structural changes upon dopamine binding and phosphorylation. The deuterium
exchange dynamics of TyrH with dopamine bound or phosphorylated at Ser40 were also
examined to gain insight into the structural changes accompanying regulation. The
peptides surrounding Ser40, 35-41 and 42-71, were not detected in the phosphorylated
protein. The reasons for this were not pursued, but phosphorylated peptides are typically
quite difficult to detect by mass spectrometry, and phosphorylation of Ser40 makes this
region of the protein more susceptible to proteolysis (102). With those exceptions, all of
the peptides, which could reproducibly be detected in the native enzyme, could also be
detected in the dopamine-bound and phosphorylated forms. Only three peptides show
significantly different exchange behavior upon dopamine binding or phosphorylation
(Figure 2.4). All three show dramatic decreases in the rates of deuterium incorporation.
Two of the fragments (35-41, 42-71) are on the regulatory domain and the other one
(295-299) is on the catalytic domain (Figure 2. 2). The altered exchange behavior of
peptide 295-299 was confirmed by the overlapping peptide 295-301. The effect of
phosphorylation on the exchange kinetics is the opposite, in that peptide 295-299 shows
more rapid deuterium incorporation upon Ser40 phosphorylation.
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Figure 2.4: Time course of deuterium incorporation into peptides 35-41, 42-72, and 295-
299 for TyrH alone (open circles), with bound dopamine (filled circles) or
phosphorylated at Ser40 (filled triangles).
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DISCUSSION
The present results provide significant insight into the structural changes
associated with regulation of TyrH and the conformational flexibility of the enzyme. We
found that the conformational changes induced by dopamine binding and Ser40
phosphorylation involve three peptides (35-41, 42-71, 295-299), and dopamine binding
and Ser40 phosphorylation have opposite effects on the dynamics of these three
peptides.
Phosphorylation-induced local conformational changes near phosphorylation
sites have been seen in many regulatory enzymes (103), and this has also been suggested
to be the case for TyrH (86). In our results, residues 35-71 are protected from the solvent
upon dopamine binding, agreeing with the limited proteolysis studies that show
dopamine binding protects Arg33 and Arg49 (86). This result is also consistent with the
observation that dopamine binding slows Ser40 phosphorylation (77). Although peptides
35-41 and 42-71 were not detected in the phosphorylated protein, Arg33 and Arg49 are
more susceptible for proteolysis after phosphorylation at Ser40, in contrast to the effects
of dopamine binding (86). The isolated catalytic domain of TyrH has a dissociation
constant for dopamine similar to that of phosphorylated TyrH (Wang and Fitzpatrick,
unpublished observation), suggesting that the regulatory domain is responsible for tight
binding of dopamine in the active site. A reasonable explanation for all of the results is
that dopamine binding and Ser40 phosphorylation have opposite effects on the structure
of the regulatory domain.
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The decreased exchange observed upon dopamine binding in respective peptides
can be explained by more hydrogen bonding to the amides or/and the amides becoming
more buried. Together with the effects on proteolysis and Ser40 phosphorylation rate, a
reasonable model to explain the H/D exchange data is that dopamine binding makes the
region surrounding Ser40 close down on the catalytic domain so that the amides in this
region are more protected from the solvent.
In the catalytic domain, peptide 295-299 was found to have decreased
incorporation of deuterium when dopamine is bound to TyrH, and increased deuterium
incorporation when TyrH is phosphorylated at Ser40 (Figure 2.4). Peptide 295-299
overlaps with one of the surface loops, 290-296, which is at the entrance of the active
(98).  Of the peptide, four amides in the peptide 295-299, the N-terminal two are in the
loop and the other two are at the beginning of a helix. The rest of the helix (300-305)
incorporated little or none deuterium under all the three conditions, which indicates that
it has little conformational flexibility. Two peptides (287-294, 287-295) on the other end
of loop 290-296 were analyzed in this study, but neither shows altered exchange
behavior upon dopamine binding or phosphorylation, suggesting that the majority of the
loop is not involved in structural changes induced by dopamine binding or
phosphorylation. Collectively, the altered exchange behavior of 295-299 is not likely to
due to the movement of loop 290-296, since that should change the exchange behavior
of peptides 287-294. Rather, the altered exchange pattern of 295-299 can be explained
by changed surface exposure due to movement of the regulatory domain. This is
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supported by the fact that the maximum exchange content of the peptide during the
experimental time-course under the three conditions is the same.
The structures of the regulatory domain and the catalytic domain of PheH are
both available, while only the structure of the catalytic domain of TyrH is available.
Insight into the structure of the regulatory domain of TyrH can be gained from
comparison of the sequences of the two regulatory domains. As shown in Figure 2.5, the
sequences of the regulatory domains of PheH and TyrH can be aligned, except that
residues 1-28 and residues 49-79 of TyrH do not have corresponding residues on PheH.
The phosphorylation sites, Ser40 of TyrH and Ser16 of PheH, are not aligned by the
default parameters of Clustal W2. This agrees with the different phosphorylation
activation mechanisms, in which Ser40 phosphorylation of TyrH facilitates dopamine
dissociation, and Ser16 phosphorylation of PheH reduces the phenylalanine
concentration required for substrate activation (91).  Peptides 35-41 and 42-71 of the
regulatory domain of TyrH show altered exchange patterns upon dopamine binding, and
residues 35-47 align well with residues 19-31 of PheH. To obtain more structural
information about residues 35-71 of TyrH, the structure of PheH containing the
regulatory domain and the catalytic domain is used. Figure 2.6 shows that, residues 19-
31 of PheH (35-47 in TyrH) lie on top of residues 249-253 (295-299 of TyrH) and
partially protects them from the solvent. This explains quite well the H/D exchange
patterns of peptides 35-41, 42-71 and 295-299. In the absence of dopamine binding or
phosphorylation, residues 35-71 is a labile loop lying on top of 295-299; upon dopamine
binding, 35-71 become less labile, restricting the accessibility of solvent both for 295-
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299 and for 35-71. Upon Ser40 phosphorylation, 35-71 becomes more flexible, leaving
295-299 more accessible to solvent. The interaction of 35-71 with 295-299 makes TyrH
more compact upon dopamine binding, leading to a shorter retention time on gel
filtration chromatography and less susceptibility to phosphorylation. In addition, the
increased flexibility due to Ser40 phosphorylation makes TyrH more accessible to
trypsin for degradation.
TyrH    1 MATPSAPSPQ PKGFRRAVSE QDAKQAEAVT SPRFIGRRQS LIEDARKERE 50
PheH    1 ---------- ----MAAVVL ENGVLSRKLS D---FGQETS YIEDNSNQ-- 31
TyrH   51 AAAAAAAAAV ASSEPGNPLE AVVFEERDGN AVLNLLFSLR GTKPSSLSRA 100
PheH   32 ---------- ---------- ---------N GAISLIFSLK –EEVGALAKV 51
TyrH  101 VKVFETFEAK IHHLETRPAQ RPLAGSPHLE YFVRFEVPSG –DLAALLSSV 149
PheH   52 LRLFEENDIN LTHIESRPSR ---LNKDEYE FFTYLDKRSK PVLGSIIKSL 98
                                 
TyrH  150 R-----RVSD DVRSAREDKV P 165 
PheH   99 RNDIGATVHE LSRDKEKNTV P 119
Figure 2.5: Sequence alignment of TyrH and PheH regulatory domains. The default
parameters of Clustal W2 (104) were used. Identical residues are in bold. The
phosphorylation sites, Ser40 of TyrH and Ser16 of PheH, are underlined. Peptides of
TyrH which showed altered H/D exchange patterns upon dopamine binding are indicated
with arrows.
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Figure 2.6. Interactions between the regulatory and catalytic domains of PheH. The
figure was generated using the PDB file 2PHM. The catalytic domain of PheH is shown
as a surface rendering in gray, while the regulatory domain of PheH is shown as a green
cartoon. Residues 249-253 are in red. The active site iron is an orange sphere.
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The exchange rate of unstructured peptides is ~ 10 s-1 (105). As a result, the
complete exchange of residues 28-71 within 10 s indicates a lack of secondary structure
of this region. Peptides after residue 71 in the regulatory domain do not show complete
exchange. The isolated TyrH regulatory domain contains a high content of β-sheet
structure (35), suggesting the β-sheet structure is formed by residues after 71. Residues
80-165 show ~ 25% sequence identity with corresponding residues in the regulatory
domain of PheH, which form a two helix and four β-sheet bundle. Residues 80-165 of
TyrH may adopt a similar structure to the corresponding residues of PheH.
The majority of the catalytic domain does not show conformational changes upon
dopamine binding or Ser40 phosphorylation. There are four loops (177-193, 316-328,
421-429, and 290-296) at the entrance of the active site, and three of them have been
shown to be functionally important. Alanine scanning studies showed that loop 178-193
of TyrH is important for catalysis (39); fluorescence anisotropy studies showed that this
loop becomes more rigid upon pterin binding (106). Thus loop 178-193 of TyrH is
important for enzyme function. Loops 421-429 and 316-328 are critical for substrate
specificity (40). When the center residues are mutated to the corresponding residues of
PheH, the protein functions more like PheH than TyrH (40). There is one more loop
(290-296) at the active site entrance. The crystal structure of  pterin-bound TyrH shows
that this loop may be involved in pterin binding (98). In the present study, this loop has
been shown to be involved in regulation of TyrH. All four loops show relatively a high
percentage of deuterium incorporation, indicating the high dynamics of these loops.
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The tetramerization domain is composed of a long helix containing ~ 26 amino acids and
a two strand β-sheet. All the peptides in this region have a similar exchange behavior,
with time-dependent incorporation of deuterium. The incorporation of deuterium into
this region could be due to the transient loosening-up of the helix and the β-sheet. The
similar exchange patterns of the helix and the β-sheet indicate that the deuterium
incorporation into the helix and the β-sheet is concerted, meaning there is transient
dissociation of the tetramer into dimers and monomers.
In conclusion, we have found three peptides in TyrH showing altered exchange
patterns upon dopamine binding or phosphorylation. Two are on the regulatory domain
surrounding the phosphorylation site Ser40, and the other one is on one of the four loops
at the active site entrance. The three peptides show more solvent accessibility upon
phosphorylation and less upon dopamine binding.
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CHAPTER III
FLUORESCENCE ANISOTROPY REVEALS EFFECTS OF SER40
PHOSPHORYLATION ON THE DYNAMICS OF A REGION IN THE
REGULATORY DOMAIN OF TYROSINE HYDROXYLASE
Tyrosine hydroxylase (TyrH) belongs to the non-heme iron-containing aromatic
amino acid hydroxylase family (4, 5). The enzyme catalyzes the hydroxylation of
tyrosine to dihyroxyphenylalanine (DOPA) using molecular oxygen and
tetrahydrobiopterin (BH4). As the first and rate-limiting enzyme in the biosynthesis of
catecholamines, regulation of TyrH activity is critical. Feedback inhibition by
catecholamines and activation by Ser40 phosphorylation are the best-established
regulatory mechanisms (77, 107). As shown in Figure 3.1, TyrH converts tyrosine into
dihydroxyphenylalanine (DOPA) using a ferrous iron in the active site (12).
Alternatively, a fraction of the ferrous enzyme can be oxidized to the ferric form (80,
81), rendering the enzyme inactive; the ferric enzyme can be reduced by BH4, making
TyrH active again (81). The ferric enzyme can also bind catecholamines in the active
site, with binding affinities ranging 1-5 nM (78, 79). This prevents the reduction by BH4,
trapping the enzyme in an inactive form. This inhibition can be reversed by Ser40
phosphorylation, which increases the catecholamine dissociation rate constant by two to
three orders of magnitude (78, 79). As a result, catecholamines can dissociate from the
active site, allowing TyrH to become active again upon reduction to the ferrous form.
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EFe(ll)
EFe(lll)
EFe(lll) catecholamine
catecholamine
O2 BH4
EFe(ll) BH4O2tyr
BH4, O2, tyr
DOPA, BH3OH
        Ser40 
phosphorylation
Figure 3.1: Regulation of TyrH.
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Previously, hydrogen-deuterium exchange mass spectrometry showed that upon
dopamine binding, residues 295-299 at the active site entrance and residues 35-71 in the
regulatory domain are protected from exchange (108). Phosphorylation of TyrH at Ser40
has the opposite effect on the exchange kinetics of residues 295-299, but residues 35-71
of the phosphorylated enzyme were not detectable by mass spectrometry (108). These
results led to a model that dopamine binding stabilizes the N-terminus of the regulatory
domain of TyrH over the active site entrance, while Ser40 phosphorylation shifts the N-
terminus of the regulatory domain away from the active site. The lack of structural
information about residues 35-71 in the phosphorylated enzyme makes the
understanding of the dynamics of the N-terminus of the regulatory domain incomplete.
Thus, a complementary method was required to study the dynamics of this region.
Fluorescence anisotropy and quenching are excellent probes of local dynamics in
proteins (109-111). We have previously shown that mutating all three intrinsic
tryptophans in TyrH to phenylalanines has little effect on enzyme activity or substrate
binding (106). We describe here the use of single tryptophan-containing enzymes to
study the effects of phosphorylation on the dynamics of the N-terminus of TyrH.
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EXPERIMENTAL PROCEDURES.
Materials. Hepes (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid) was
obtained from USB Co. (Cleveland, OH). Ultrapure glycerol and N-acetyl-L-
tryptophanamide were from Sigma-Aldrich Chemical Co. (St. Louis, MO). All the other
chemicals were of the highest purity commercially available.
Protein purification. The plasmid for expression of mutant TyrH with the three
intrinsic tryptophans replaced by phenylalanines has been described previously (106).
The introduction of a single tryptophan at position 14, 34 or 74 was performed by
QuikChange site-directed mutagenesis (Stratagene). The purification of the mutant
enzymes was modified from that described previously for wild-type TyrH (93). After the
heparin column, the enzymes were incubated with a 1.2 molar ratio of ferrous iron,
followed by further purification with a Q-Sepharose column (10 × 200 mm) (108).
Phosphorylation and purification of the phosphorylated enzymes were performed as
previously described (78, 108). The purified protein was dialyzed into 50 mM Hepes,
100 mM KCl and 10% ultrapure glycerol, pH 7.3 for the fluorescence experiments.
Kinetic assays. The enzyme activity was determined using a colorimetric end-
point assay at pH 7 and 30 oC as previously described (41).  The dopamine dissociation
rate constants were determined by monitoring the decrease in absorbance at 550 nm after
the enzyme-dopamine complex was mixed with excess dihydroxynaphthalene at pH 7
and 10 oC as previously described (78).
Fluorescence analyses. Steady-state anisotropies and the effects of acrylamide as
a quencher were determined on a Koala Spectrophotometer (ISS, Urbana Champaign,
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IL) with a 300 W Xenom lamp as the excitation source, using 2-5 µM enzyme in 50 mM
Hepes, 10% glycerol and 100mM KCl at 22 oC. For anisotropy measurements, samples
were excited with vertically polarized light at 300 nm with a slit width of 4 nm. The
emission intensity of both horizontally (IH) and vertically (IV) polarized light were
measured, and the anisotropy, r, was subsequently calculated using Equation 3.1.For the
quenching studies, samples were excited at 300 nm, and the emission intensity, F, was
measured with a Schott WG-345 filter at various acrylamide concentrations Q.
Subsequently, KSV and kq were calculated using Equation 3.2 and 3.3, respectively.
Here, F0 is the fluorescent intensity in the absence of acrylamide, KSV is the Stern-
Volmer constant, τ is the lifetime of the fluorophore, and kq is the bimolecular
quenching rate constant.
r = (IV - IH)/(IV + IH) (3.1)
F0/F = 1 + KSV × [Q] (3.2)
KSV = kq × τ (3.3)
Lifetime and dynamic anisotropy experiments were performed using a K2
fluorometer with multi-frequency phase and modulation (ISS, Urbana Champaign, IL).
The excitation light of 300 nm was generated from a light-emitting diode, and the
emission was collected through a Schott WG-345 filter and a polarizer at an angle of
35o. An N-acetyl-L-tryptophanamide (NATA) solution in 5 mM sodium phosphate (pH
7.0) was used as reference with a lifetime of 2.85 ns. Data were collected between 1 and
250 MHz. The calculations of the lifetimes were performed using a continuous
Lorentzian distribution model, since it gave the best χ2 value for all the conditions.
49
Analyses of the dynamic anisotropy data were performed using the software from Global
Unlimited (Urbana Champaign, IL).
RESULTS
Activities of single-tryptophan enzymes. There are three tryptophan residues in
TyrH, at positions 166, 233 and 372. Mutation of all three to phenylalanine yields a
tryptophan-free enzyme (F3W TyrH) with wild-type enzyme activity (106). Three single
tryptophan-containing enzymes were constructed by replacing each of the three aromatic
amino acids in the regulatory domain of F3W TyrH, Phe14, Phe34 and Phe74, with
tryptophan, yielding F14W/F3W TyrH, F34W/F3W TyrH and F74W/F3W TyrH. The
mutant enzymes have comparable kcat and Km values to wild-type TyrH (Table 3.1),
suggesting that catalysis and substrate binding are not altered by the mutations. The
dopamine dissociation rate constants were used as an indicator of the regulatory function
of the mutants. Dopamine binds to TyrH to form a greenish complex, with an absorption
maximum of 690 nm, whereas dihydroxynaphthalene (DHN) binds to TyrH to form a
complex with an absorption maximum of 550 nm. As a result, the increase of absorbance
at 550 nm when a large excess of DHN is added to the enzyme-dopamine complex can
be used to measure the dopamine dissociation rate constant. Adding DHN to the
dopamine complexes of the unphosphorylated mutant enzymes results in a slight
increase in absorbance at 550 nm but no decrease in absorbance at longer wavelengths
over 10 h, indicating that the mutants are denaturing during the reaction. Still, these
results allow us to set an upper limit on the dissociation rate constants for the
50
unphosphorylated enzymes of 10-5 s-1. Upon phosphorylation, the dissociation rate
constants for all three mutants increase to close to the value for wild-type TyrH (Table
3.1), establishing that the regulatory functions of the mutant enzymes are not
significantly altered by the mutations.
Table 3.1 : Steady-state kinetic parameters and dopamine dissociation rate constants of
F14W/F3W TyrH, F34W/F3W TyrH and F74W/F3W TyrH.
103 koff
c (s-1)Enzyme KPH4
a
(µM)
Ktyr
b
(µM)
kcat
(min-1)
unphosphorylated phosphorylated
wild-type 45 ± 8 47 ± 6 138 ± 5 0.0007d 0.87 ± 0.02
F14W/ F3W 55 ± 8 24 ± 4 109 ± 4 <0.01 0.38 ± 0.02
F34W/ F3W 77 ± 7 58 ± 4 121 ± 3 <0.01 0.39 ± 0.01
F74W/ F3W 65 ± 7 43 ± 6 104 ± 4 <0.01 0.40 ± 0.01
Conditions: a50 mM Hepes, pH 7, 1 mM DTT, 10 µM ferrous ammonium sulfate, 10
µg/ml catalase, 100 µM tyrosine with 5 to 400 µM 6-MePH4 at 25 
oC; b50 mM Hepes,
pH 7, 1 mM DTT, 10 µM ferrous ammonium sulfate, 10 µg/ml catalase, 400 µM 6-
MePH4 with 5 to 400 µM tyrosine at 25 
oC; c50 mM Hepes, pH 7, 100 mM KCl, 10%
glycerol, ~30 µM enzyme, 45 µM dopamine, 30 µM DPTA, 1mM DHN at 10 oC; d from
reference (112), at 15 oC.
Fluorescent quenching with acrylamide. Acrylamide quenching was used as a
probe for changes in solvent accessibility of the individual tryptophan residues upon
phosphorylation. The results are shown as Stern-Volmer plots in Figure 3.2. The values
of the Stern-Volmer quenching constants (KSV) for the mutant enzymes were determined
from the slopes of the plots and are given in Table 3.2. Phosphorylation does not affect
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the KSV value for F74W/F3W TyrH. In contrast, phosphorylation results in an increase of
12% in the KSV value for F34W/F3W TyrH and a smaller decrease (~5%) in the KSV
value for F14W/F3W TyrH.
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Figure 3.2: Fluorescence quenching by acrylamide of F14W/F3W TyrH, F34W/F3W
TyrH and F74W/F3W TyrH. Open symbols, unphosphorylated enzyme; solid symbols,
phosphorylated enzyme.
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Table 3.2: Effects of phosphorylation on the fluorescence parameters of F14W/F3W
TyrH, F34W/F3W TyrH and F74W/F3W TyrH.
enzyme Ksv (M
-1) τ (ns) kq (M
-1ns-1) anisotropy r0 - r∞ θ1 (ns)
F14W/
F3W
5.01 ± 0.03 3.26 ± 0.10 1.53 ± 0.05 0.185 ±
0.004
0.060 ±
0.008
1.27 ±
0.15
pF14W/
F3W
4.76 ± 0.02 3.40 ± 0.02 1.40 ± 0.01 0.177 ±
0.001
0.069 ±
0.009
1.27 ±
0.15
F34W/
F3W
4.94 ± 0.05 3.35 ± 0.09 1.47 ± 0.04 0.198 ±
0.002
0.061 ±
0.002
1.00 ±
0.09
pF34W/
F3W
5.59 ± 0.08 3.46 ± 0.02 1.62 ± 0.02 0.168 ±
0.001
0.080 ±
0.002
1.00 ±
0.09
F74W/
F3W
3.28 ± 0.04 2.71 ± 0.05 1.21 ± 0.02 0.234 ±
0.003
0.048 ±
0.007
1.62 ±
0.12
pF74W/
F3W
3.30 ± 0.05 2.75 ± 0.02 1.20 ± 0.02 0.232 ±
0.004
0.036 ±
0.006
1.62 ±
0.12
The phosphorylated enzymes have a lower case p in the front of the names.
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Fluorescence lifetimes. The fluorescence lifetimes of the unique tryptophan
residues in each of the three mutants were determined using the multi-frequency domain
method, in which phase and modulation are measured as a function of the excitation
frequency. The fluorescence lifetimes (τ) were analyzed as continuous Lorentzian
distributions with width W and central lifetimes C (113-115). F14W/F3W TyrH and
F34W/F3W TyrH have comparable lifetimes of ~3.4 ns, while F74W/F3W TyrH has a
shorter lifetime of 2.7 ns (Table 3.2). The lifetimes of F14W/F3W TyrH and F34W/F3W
TyrH  both increased by ~ 0.1 ns upon Ser40 phosphorylation, while the lifetime of
F74W/F3W TyrH was not altered upon phosphorylation. Knowledge of the lifetimes
allows the Ksv values in Table 3.2 to be converted to the bimolecular quenching rate
constants (kq) using Equation 3. These are listed in Table 3.2. Ser40 phosphorylation
decreased the kq value of F14W/F3W TyrH by 8%, but increased the kq value of
F34W/F3W TyrH by 10%. The kq value of F74W/F3W TyrH was not altered by Ser40
phosphorylation. In addition, it is significantly smaller than the kq values of the other
two mutant proteins.
Steady-state anisotropy. Steady-state fluorescence anisotropy was performed in
order to probe the impact of phosphorylation on the local flexibility of the three
positions. A decrease in the local flexibility of the peptide backbone attached to a
tryptophan residue is expected to result in an increase in the anisotropy of the
tryptophan. The results are summarized in Table 3.2. When only the values for the
unphosphorylated proteins are considered, F74W/F3W TyrH has a much larger
anisotropy value than the other two proteins, suggesting that residue 74 is in a more rigid
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local environment. Phosphorylation results in a small decrease in the anisotropy of the
tryptophan at position 14, while the anisotropy at position 74 is unaffected by
phosphorylation (Table 3.2). In contrast, the anisotropy at position 34 is significantly
smaller in the phosphorylated enzyme. This decrease of anisotropy is consistent with an
increase in the flexibility at this position upon phosphorylation.
Dynamic anisotropy. To further quantify the rotational properties of each
tryptophan and the effect of phosphorylation, the dynamic anisotropy of each was
determined. The phase difference and modulation ratio as a function of frequency for
each protein are shown in Figure 3.3. With the exception of the data at the highest
frequency used, the dynamic anisotropies of F14W/F3W and F74W/F3W TyrH are not
affected by phosphorylation. In contrast, phosphorylation resulted in a substantial
change in the dynamic anisotropy F34W/F3W TyrH at all frequencies. These results
agree with the effects of phosphorylation on the steady-state anisotropies.
The data in Figure 3.3 were analyzed using equation 3.4, which applies for a
system with a global rotation plus a hindered local rotation (116, 117). Here, r0 is the
anisotropy at time zero and is independent of the rotational motion, r∞ is the anisotropy
persisting after a relative long time (t >> θ1), and θ1 and θ2 are the local and global
rotational correlation times (θ1 << θ2). Thus, r∞ and r0 - r∞ are the contributions of the
slow global rotation and the faster local rotation, respectively. The value of θ2, which
reflects the motion of the entire protein, was fixed at 115 ns based on our earlier study of
the fluorescence properties of TyrH (106). The values of r0 and θ1 from independent
analyses of the phosphorylated and unphosphorylated enzymes were similar, so a global
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analysis of the data was performed for each mutant protein, combining the data for the
phosphorylated and unphosphorylated forms and assigning the same r0 and θ1
irrespective of phosphorylation status. The analyses yielded the same r0 value of 0.21 ±
0.01 for all three proteins, but the θ1 and r∞ values differed (Table 3.2). Only in the case
of F34W/F3W TyrH is there a significant increase in the value of r0 - r∞ upon
phosphorylation (Table 3.2). However, the errors in the values of r0 - r∞ for F14W/F3W
TyrH and F74W/F3W TyrH from the analyses are larger than that for F34W/F3W TyrH;
this is clearly reflected by the poorer quality of the fitting for these two proteins (Figure
3.3). The inability to fit the data may come from the limitations of describing the
rotational behavior of the two mutants with only one global rotation component and one
local hindered rotation component. However, using models with more local hindered
rotations to fit the data did not significantly improve the fitting. Still, the raw data clearly
show that Ser40 phosphorylation has a much larger effect on the dynamic anisotropy of
F34W/F3W TyrH compared to F14W/F3W TyrH and F74W/F3W TyrH.
r(t) = (r0 - r∞)e
-t/θ1 + r∞e
-t/θ2 (3.4)
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Figure 3.3: Dynamic anisotropy of F14W/F3W TyrH, F34W/F3W TyrH and F74W/F3W
TyrH. Open symbols, unphosphorylated enzyme; solid symbols, phosphorylated
enzyme.
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DISCUSSION
Previous analyses using hydrogen/deuterium exchange mass spectrometry
(HDMS) established that regulation of TyrH by Ser40 phosphorylation and
catecholamine binding are accompanied by structural rearrangements. Three peptides
were shown to be involved in the structural changes accompanying dopamine binding
(108). Two of the three peptides (peptide 35-41 and peptide 42-71) are in the N-terminus
of the regulatory domain, while the other (peptide 295-299) is in the catalytic domain at
the entrance to the active site. Upon dopamine binding all three become less accessible
to solvent, consistent with the regulatory domain closing down over the active site in the
dopamine-inhibited enzyme. When similar analyses were carried out with the
phosphorylated enzyme, the catalytic domain peptide exhibited greater exchange,
consistent with greater solvent exposure of the active site. While this provides evidence
for movement of the regulatory domain away from the active site upon phosphorylation,
the two peptides encompassing residues 35-71 in the regulatory domain could not be
detected by mass spectrometry. The present fluorescence studies of the three single
tryptophan mutants of TyrH provide insight into changes in the local dynamics of the N-
terminus of the regulatory domain upon phosphorylation and substantiate the earlier
model.
Similar to HDMS, which probes the solvent accessibility of amide hydrogens in
peptide bonds, fluorescence quenching by acrylamide probes the accessibility of the
fluorophore, tryptophan in the present case. F34W/F3W TyrH exhibits an increase in kq
upon Ser40 phosphorylation, suggesting that Ser40 phosphorylation increases the
58
flexibility of the region surrounding position 34. This is confirmed by both the steady-
state and dynamic anisotropy analyses. Since phosphorylation increases the lifetime of
F34W/F3W TyrH by only 0.1 ns, the change in anisotropy of F34W/F3W TyrH upon
phosphorylation can be attributed solely to a change in the rotational freedom of the
indole ring. The dramatic decrease in the steady-state anisotropy upon phosphorylation
of F34W/F3W TyrH reflects an increase in the rotational motion of the side chain of the
residue at position 34. The increase in the value of r0 - r∞ after phosphorylation of
F34W/W3 TyrH can be more directly attributed to an increase in the flexibility at
position 34 upon Ser40 phosphorylation. The increase in flexibility upon
phosphorylation of TyrH is consistent with decreased interaction of the N-terminus of
the regulatory domain with the catalytic domain.
There is a small decrease in the value of kq for F14W/F3W TyrH upon Ser40
phosphorylation, suggesting that this portion of the protein is more protected from
solvent. In contrast, phosphorylation results in a very small decrease in the steady-state
anisotropy, suggesting an increase in flexibility. There is also a small increase in the r0 -
r∞ value upon phosphorylation, again suggesting a small increase in flexibility, but the
relatively large errors in values of r0 - r∞ preclude drawing a definitive conclusion from
the change the latter value. Overall, the data suggest that there is a small structural
change in the region around residue 14 upon Ser40 phosphorylation, but it cannot be
simply described as increased motion of the side chain at that position.
Peptides 28-34 and 35-41 undergo complete exchange with solvent deuterium
within 7 s (108), indicating that the surrounding region is very flexible. The values of kq
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and r0 - r∞ at position 14 are comparable to those for position 34 in the unphosphorylated
protein, indicating that the region around residue 14 is also very flexible. Ser19 is
another phosphorylation site on the regulatory domain, and phosphorylation of TyrH at
Ser19 is required for binding to 14-3-3 proteins (75). 14-3-3 protein binding (118)
decreases the rate of dephosphorylation at Ser40 and Ser19 by phosphatases by
decreasing the solvent accessibility of those regions (72, 76). Recent studies show that
more than 90% of 14-3-3 binding proteins have unstructured regions (119), and the
binding sites of 14-3-3 proteins are usually in those unstructured regions (119). CD
analyses of the regulatory domain of TyrH indicate that ~ 45% of the regulatory domain
is non-structured (76). Together with our results, it would be reasonable that region
surrounding position 14 does not have a rigid structure so that it may bind 14-3-3
proteins.
Neither the acrylamide quenching nor the anisotropy suggest that there are
significant differences in the flexibility of the residue at position 74 upon
phosphorylation. Compared with F14W/F3W TyrH and F34W/F3W TyrH, F74W/F3W
TyrH has dramatically smaller values of kq and r0 - r∞. This is consistent with position 74
being in a more rigid environment than position 14 and 34. The present results are
consistent with the HDMS results, in which peptide 75-83 shows less deuterium
incorporation than peptide 28-34, and neither dopamine binding nor phosphorylation
alters the deuterium incorporation content into peptide 75-83. Theoretically, a less
exposed fluorophore should have an increased lifetime, but the lifetime of F74W/F3W
TyrH is ~ 0.7 ns smaller than the lifetimes of the other two proteins in this study.
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Lifetimes can be influenced by many factors other than solvation. Intermolecular
interaction with nearby side chains groups (e.g. histidyl, carboxyl groups) tend to quench
a fluorophore (114), resulting in a decreased lifetime. The indole ring could also be
quenched from a distance by the protein-bound iron in TyrH (114). As a result, lifetimes
are not a reliable indicator for local environment.
Both the previous HDMS data and the present fluorescence results support a
regulation-driven shift between a closed conformation and an open conformation for
TyrH (Figure 3.4). In this model, dopamine binding stabilizes a closed form of the
enzyme in which the N-terminus of the regulatory domain covers the active site
entrance, while Ser40 phosphorylation shifts the protein to an open form in which the N-
terminus of the regulatory domain has moved away from the active site. Phosphorylation
results in smaller differences in solvent accessibility than dopamine binding (108),
suggesting that the resting enzyme is closer to the open form. This agrees with the
observation that deletion of the regulatory domain of TyrH has little effect on the steady-
state kinetic parameters (35, 93), indicating that the regulatory domain of the resting
enzyme does not restrict substrates from accessing the active site.
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Figure 3.4. Interactions between the regulatory domain and the catalytic domain of
PheH. The catalytic domain is shown as surface rendering and the regulatory domain is
shown as cartoon. The active site iron is shown as an orange sphere. Residues of the N-
terminus of the regulatory domain are shown in red. Residues 249-253 (295-299 in
TyrH) are shown in blue. The image was generated from PDB file 2PHM.
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The dissociation rate constants for catecholamines increase several hundred-fold
upon phosphorylation (78, 79). The rate constant for dissociation of dopamine from
TyrH lacking the regulatory dopamine is half of that of Ser40-phosphorylated TyrH
(Wang and Fitzpatrick, unpublished data), suggesting that the restricting effect of the
regulatory domain in the closed form is responsible for tight binding of catecholamines.
Previous studies show that the amino group of catecholamines is critical for tight binding
(108). Crystal structures of the catalytic domain of PheH with catecholamine show that
the amino group protrudes out of the active site, lacking any interaction with the
catalytic domain (120). These results suggest that there is a direct interaction between
the regulatory domain and the amino group of catecholamines in the closed form of
TyrH.
Studies of the dynamic anisotropy at position 184 of unphosphorylated TyrH
have been carried out previously (106). Position 184 is at the center of one of the surface
loops near the active site entrance and this loop has been shown to be required for
catalysis (39). The value of r0 - r∞ at position 184, 0.048, is comparable to the value at
position 74. Residues in loops are usually more dynamic than those in the secondary
structures, indicating that position 74 is in a relatively dynamic region. Compared with
position 184, the significantly larger values of r0 - r∞ for positions 34 and 14 indicate that
these two positions are highly dynamic, consistent with the peptides containing these
residues lacking a stable structure. Taken together, our results suggest that the entire N-
terminal half of the regulatory domain is highly flexible.
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In conclusion, we have used three single-tryptophan mutants of TyrH to
investigate the structural effects of Ser40 phosphorylation of TyrH. The results show that
the region near residue 34 has greater flexibility upon phosphorylation, while the regions
near residue 14 and residue 74 do not undergo structural rearrangement upon
phosphorylation. This is consistent with TyrH existing in open and closed
conformations, the equilibrium between which is critical to regulation.
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CHAPTER IV
IDENTIFICATION OF A DIMERIZATION DOMAIN WITHIN THE
REGULATORY DOMAIN OF TYROSINE HYDROXYLASE
Tyrosine hydroxylase (TyrH) converts tyrosine into dihydroxyphenylalanine
(DOPA) utilizing tetrahydrobiopterin and molecular oxygen (5, 21, 121). This is the first
and rate-limiting step in the synthesis of catecholamine neurotransmitters. TyrH is a
member of the small family of aromatic amino acid hydroxylases that also includes
phenylalanine hydroxylase (PheH) and tryptophan hydroxylase (TrpH). PheH is the rate-
limiting enzyme of phenylalanine catabolism and TrpH is the rate-limiting enzyme of
serotonin biosynthesis. As a result, the three enzymes are related to many human
diseases, such as Parkinson’s disease (122) and phenylketonuria (123).
The mammalian forms of these enzymes contain regulatory domains at their N-
termini and catalytic domains at their C-termini. The catalytic domains contain all the
residues for catalysis (93), while the regulatory domains are responsible for allosteric
regulation (5). The mammalian forms of these enzymes are homotetramers (95, 124),
although PheH is also reported to be a mixture of tetramers and dimers (125, 126). The
removal of the N-termini does not change the oligomerization state of the proteins (14,
35, 127-129), while further truncation of the C-terminal coiled coil yields monomeric
proteins in solution (24, 26, 32, 36) or dimeric PheH in crystals (13). Although the
sequences of the catalytic domains of the rat enzymes are ~ 50% identical, the regulatory
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domains of the three enzymes are not homologous (15, 16), consistent with their
different regulatory mechanisms (5).
As the rate-limiting enzyme in the catecholamine synthetic pathway, TyrH is
under tight regulation (4). The active site of TyrH contains a non-heme iron atom that
must be in the ferrous form for catalysis (12, 80). Molecular oxygen oxidizes ferrous
TyrH to the ferric form (80), which has a high affinity for catecholamines (78, 79). The
binding of a catecholamine to the ferric active site iron prevents the reduction of TyrH to
the ferrous form, trapping TyrH in the ferric form (77). Phosphorylation of TyrH at
serine 40 increases the rate constant for dissociation of catecholamines by as much as
three orders of magnitude (78, 79). This allows the catecholamine to dissociate from the
enzyme and the enzyme to be reactivated. A crystal structure is only available for the C-
terminal catalytic domain of TyrH (14). Limited proteolysis and hydrogen deuterium
exchange mass spectrometry (HDMS) have shown that the movement of the first ~ 70
residues is directly involved in regulation (86, 108). These residues have been proposed
to function like a lid that closes the entrance to the active site after a catecholamine is
bound, making the dissociation of the catecholamine extremely slow. Upon Ser40
phosphorylation, the lid opens, facilitating the exit of the catecholamine.
Residues 70 - 150 of TyrH were recently proposed to be an ACT domain (29,
130). ACT domains are typically involved in regulation of amino acid metabolism (131);
binding the amino acid directly to the ACT domain can either increase or decrease the
amino acid metabolism  (131). Pre-incubation of PheH with phenylalanine activates the
enzyme, and this activation can be abolished by deletion or mutation of the ACT domain
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in the regulatory domain (132-134). However, whether there is a direct interaction
between phenylalanine and the ACT domain is under debate (123, 135, 136). The
function of this domain in TyrH has not been established. We describe here the
identification of a dimerization domain within the ACT domain of TyrH.
EXPERIMENTAL PROCEDURES
Materials. Porcine stomach pepsin A was purchased from Worthington
Biochemical Co. (Lakewood, NJ). Deuterium oxide (D2O, 99% D) was purchased from
Cambridge Isotope Laboratories (Andover, MA). Hepes (4-(2-hydroxyethyl)-1-
1piperazineethanesulfonic acid) was purchased from USB Co. (Cleveland, OH).
Tyrosine, phenylalanine and glycerol were from Sigma-Aldrich Chemical Co. (St. Louis,
MO). All other materials were of the highest purity commercially available.
Protein purification. Wild-type TyrH, the N-terminal truncation mutants Δ32
TyrH and Δ68 TyrH, and the regulatory domain of TyrH were purified as previously
described (20, 33, 35); the C-terminal deletion mutant 54k TyrH (lacking the last 20
amino acids) was purified using the same protocol as for wild-type TyrH. The
purification of Δ155 TyrH (deleting the N-terminal regulatory domain) was as described
previously with modifications (35). A Q-Sepharose column (10 × 300 mm) was used
instead of a DEAE-Sepharose column; this was eluted with a linear gradient from 0 to 1
M KCl in 50 mM Hepes, 10 % glycerol. A Sephacryl S-300 gel-filtration column (20 ×
600 mm) was used instead of a MonoQ column; this was eluted with 50 mM Hepes, 10
% glycerol and 100 mM KCl. To make apo-proteins, the purified wild-type TyrH or
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Δ155 TyrH was dialyzed against 50 mM Hepes (pH 7.3), 10 % glycerol and 2 mM
EDTA for three changes, followed by three changes of 200 mM Hepes (pH 7.3), 10 %
glycerol and 100 mM KCl. The iron content of these two proteins was ≤ 5% as
determined by atomic absorbance (80). All the other proteins contained a stoichiometric
amount of ferric iron.
Hydrogen deuterium exchange mass spectrometry. Here, both wild-type TyrH
and Δ155 TyrH were used to study the structural influence of tyrosine binding. A
stoichiometric amount of 6 mM Fe(NH4)2SO4 was added to 300 µM apo-protein in 200
mM Hepes (pH 7.3), 10 % glycerol and 100 mM KCl, under an argon atmosphere. To
obtain tyrosine-bound protein, tyrosine was added to the protein solution to a final
concentration of 400 µM. D2O buffers with/without 400 µM tyrosine were made
anaerobic by alternating vacuum and argon flushing before adding to enzyme. The rest
of the experiment was performed as previously described (108), except that all
procedures before quenching with 300 mM H3PO4 at 4 
oC were under anaerobic
conditions. The errors were calculated from the repeat of each condition.
Data analysis. The raw data from MS was first processed with the Thermo
Finnigan Xcalibur software, and the spectrum of individual peptide was transferred to
program MagTran to calculate the number of deuterium incorporation. The back
exchange was corrected as previously described (108). The time dependent incorporation
of deuterium of each peptide was fitted to Equation 1, where N is the maximum number
of exchangeable amide hydrogens of the timecourse, and A and B are the numbers of
amide hydrogen having exchange rate constants k1 and k2, respectively.
68
Y = N – Ae-k1t – Be-k2t (4.1)
Gel-filtration chromatography. Apparent molecular weights were determined by
chromatography on a Superdex-200 gel filtration column (16 × 600 mm or 10 × 300
mm) equilibrated with 50 mM Hepes, 100 mM KCl and 10 % glycerol at 25 oC. When
the effect of tyrosine or phenylalanine was to be determined, enzyme was incubated in
the same buffer for 30 min at 4 oC before being loaded onto the column. The column
buffer also contained phenylalanine or tyrosine at the same concentration. The proteins
used as standards were apo-ferritin, catalyse, β-amylase, aldolase, bovine serum albumin
(BSA), carbonate anhydrase and ribonuclease A.  Repeated chromatography of
individual proteins was performed to calculate the errors.
RESULTS
Hydrogen deuterium exchange mass spectrometry (HDMS) of wild-type TyrH
and Δ155 TyrH. To detect substrate-induced conformational changes of TyrH by
tyrosine, we carried out an HDMS experiment using wild-type TyrH and Δ155 TyrH.
Under anaerobic conditions, concentrated enzyme alone or with 400 µM tyrosine was
diluted 20 fold into D2O buffer containing the same concentration of tyrosine. Aliquots
were subsequently removed and quenched with cold buffer at pH 2.4. Subsequently, the
protein was proteolzed by pepsin and the peptides were separated by HPLC before
detection by MS. For wild-type TyrH, the addition of tyrosine has no effect on the
kinetics of deuterium incorporation into the majority of the peptides except peptide 342-
348, which exhibits increased deuterium incorporation upon tyrosine binding (Figure
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4.1). When Δ155 TyrH is used, in addition to peptide 342-348 (Figure 4.1), the
deuterium incorporation of peptides in the entire tetramerization domain changes
dramatically. The exchange pattern changes from EX2 to EX1 (Figure 4.2), and more
deuterium is incorporated (Figure 4.3).
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Figure 4.1: Deuterium incorporation into peptide 342-348 of wild-type TyrH (left) and
Δ155 TyrH (right) in the absence (open symbols) and presence (closed symbols) of 400
µM tyrosine. Fitting data to Equation 4.1 generated the curves.
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Figure 4.2: HDMS spectra of residues 488-498 of Δ155 TyrH in the absence (left) and
presence (right) of 400 µM tyrosine.
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Figure 4.3: Deuterium incorporation into the tetramerization domain of Δ155 TyrH in
the absence (open circles) and presence (closed circles) of 400 µM tyrosine. The
exchange reaction was carried out at 25 o C in 95% D2O (200 mM Hepes, pD 7.7) in the
presence (solid symbols) or absence (open symbols) of 400 µM tyrosine. Fitting data to
Equation 4.1 generated the curves.
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Gel-filtration chromatography of Δ155 TyrH and wild-type TyrH. Gel-filtration
chromatography was used to determine the influence of tyrosine on the quaternary
structures of Δ155 TyrH and wild-type TyrH. The enzymes were incubated with or
without the amino acid for 30 min at 4 oC before being loaded onto a Superdex-200
column. In the absence of tyrosine, Δ155 TyrH elutes as three major peaks with apparent
molecular weights of 423 ± 12 kDa, 162 ± 5 kDa and 45 ± 3 kDa (Figure 4.4, top); a
smaller peak with a molecular weight of 91 ± 5 kDa is also present (Figure 4.4, top). In
presence of 500 µM tyrosine, the 162 kDa peak is much smaller and the 45 kDa peak
increases dramatically (Figure 4.4, top). The molecular weights of the 162 kDa and 45
kDa species are consistent with tetramer and monomer, respectively, while the molecular
weights of 420 kDa and 91 kDa could be explained by aggregated protein and a dimer.
The 162 kDa and 45 kDa peaks were collected individually and concentrated. Re-
chromatography of each individual peak in the presence and absence of 500 µM tyrosine
reproduced the elution patterns seen in Figure 4.4 (results not shown). When different
concentrations of tyrosine are used, a concentration dependent-dissociation of Δ155
TyrH is observed (Figure 4.4, top). The same dissociation effects could also be achieved
by 1 mM phenylalanine, but not by alanine at concentrations up to 2 mM. A stable
baseline could not be obtained using tyrosine at low protein concentration if the
maximum A280 value of the peak was below 0.005. As a result, phenylalanine was used
instead of tyrosine in those situations. When the concentration of Δ155 TyrH is lowered
by about 5 fold, the protein trends to dissociate more both in the absence and in the
presence of the amino acid (Figure 4.4, bottom). When the analysis is carried out with
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wild-type TyrH, a major peak with a molecular weight of 246 ± 7 kDa and a very small
peak with a molecular weight of 86 ± 5 kDa are seen (Figure 4.5). The presence of
phenylalanine slightly increases the size of the smaller peak.
Gel-filtration chromatography of C-terminal truncation mutant. To further
elucidate the contribution of the regulatory domain to the oligomerization state of TyrH,
a mutant protein lacking 20 residues at the C-terminus (54k TyrH) was analyzed by gel-
filtration. The kcat value (37 min
-1) of this mutant is about 30% of wild-type TyrH and
the Km value for tyrosine (12 µM) is comparable to wild-type TyrH.  For experiments
with 2 - 4 µM protein injected onto the column, phenylalanine was used instead of
tyrosine to take advantage of its low extinction coefficient at 280 nm. Gel-filtration
chromatography of 54k TyrH at a concentration of ~ 3 µM revealed two peaks with
apparent molecular weights of 132 ± 10 kDa and 85 ± 8 kDa (Figure 4.6, top),
respectively; the peak with molecular weight of 132 kDa was dominant (Figure 4.6,
bottom) when the initial protein concentration was increased by ~ 20-fold. An elongated
shape for the monomer of 54k TyrH could account for the apparent size of 85 kDa and a
dimer with two monomers side by side would have an apparent size of 132 kDa.
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Figure 4.4: Effects of tyrosine binding on the quaternary structure of Δ155 TyrH. Top:
After pre-incubation in 50 mM Hepes, 100 mM KCl, 10 % glycerol and 0, 8, 15, 25, 50,
100, 200, 500 µM tyrosine for 30 min, 100 µl of 15 µM Δ155 TyrH was injected and
eluted with the same buffer in a Superdex-200 gel filtration column (10 × 300 mm). The
dotted line and broken line represent the elution buffer containing 0 and 500 µM
tyrosine, respectively. Inset: Maxium absorbance of tetramer (open symbols) and
monomer (solid symbols) of Δ155 TyrH at each tyrosine concentration. Bottom: 500 µl
of ~ 4 µM Δ155 TyrH was injected onto a Superdex-200 gel filtration column (16 × 600
mm) in the absence (dotted line) and the presence (broken line) of 1 mM phenylalanine.
75
0
0.001
0.002
0.003
0.004
0.005
0.006
50 55 60 65 70 75 80 85 90
A
28
0
ml
Figure 4.5: Analysis of the influence of phenylalanine on the quaternary structure of
wild-type TyrH. Five hundred µl of ~ 2 µM wild-type TyrH was eluted with 50 mM
Hepes, 100 mM KCl and 10 % glycerol in the absence (open symbols) and presence
(solid symbols) of 1mM phenylalanine.
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Figure 4.6: Analysis of the quaternary structure of 54k TyrH by gel-filtration. Top: Five
hundred µl of ~ 3 µM 54k TyrH was eluted with 50 mM Hepes, 100 mM KCl and 10 %
glycerol in the absence (open symbols) and presence (solid symbols) of 1 mM
phenylalanine. For comparison, the peak of the latter is normalized to have a same
maxium aborbance to the former (less than 5% difference before normalizaztion);
bottom: Five hundred µl of 50 µM 54k TyrH was eluted with 50 mM Hepes, 100 mM
KCl, 10 % glycerol and 1mM phenylalanine.
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Gel-filtration chromatography of N-terminal truncation mutants. To further
locate the dimerization domain on the regulatory domain, two mutant proteins lacking
the N-terminal 32 or 68 residues, Δ32 TyrH and Δ68 TyrH, were analyzed. Gel-filtration
chromatography of Δ32 TyrH revealed a major peak with a molecular weight of 223 ± 4
kDa and a very small peak with a molecular weight of 65 ± 3 kDa. The presence of 1
mM phenylalanine slightly increases the size of the smaller peak (Figure 4.7), like wild-
type TyrH. A similar experiment with Δ68 TyrH showed a major peak with a molecular
weight of 198 ± 6 kDa and a smaller peak with a molecular weight of 58 ± 8 kDa (Figure
4.7); the smaller peak increased in altitude in the presence of 1 mM phenylalanine
(Figure 4.7), although it is still a small peak. The major peaks of Δ32 TyrH and Δ68
TyrH are consistent with tetramers; the smaller peaks represent monomers with
elongated shapes.
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Figure 4.7: Analysis of the influence of phenylalanine on the quaternary structures of
Δ32 TyrH and Δ68 TyrH by gel-filtration. Five hundred µl of ~ 2 µM Δ32 TyrH (top) or
Δ68 TyrH (bottom) was loaded onto a Sephadex-200 gel filtration column (16 × 600
mm) and eluted with 50 mM Hepes, 100 mM KCl and 10 % glycerol in the absence
(open symbols) or presence (solid symbols) of 1 mM phenylalanine.
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DISCUSSION
The regulatory domain of TyrH is required for the modulation of enzyme
activity, e.g, feedback inhibition by catecholamines or activation by phosphorylation (5).
Phosphorylation on serine residues of the regulatory domain has also been related to
protein stability (137). But modulation either of enzyme activity or stability is related to
only the first 70 residues, and the function of residues 70-155 of the regulatory domain
in TyrH is unclear. In this paper, we report a new function of residues 70-155 of the
regulatory domain, dimerization.
The increase of deuterium incorporation into the tetramerization domain of Δ155
TyrH in the presence of tyrosine indicates an increase in flexibility in this region upon
tyrosine binding. The EX1 exchange pattern is usually seen in studies of unfolding
where a high concentration of denaturant is present and the refolding rate constant is
much smaller than the exchange rate constant of the unfolded peptide (138). In the
present case, the EX1 kinetics suggests dissociation of the tetramer. This is confirmed by
the gel-filtration chromatography, in which Δ155 TyrH dissociates into monomers upon
tyrosine binding. The dissociation seen in gel-filtration chromatography indicates that
the refolding/re-association of the tetramerization domain is a slow process; otherwise, a
clear monomer peak would not be present in the gel-filtration profile. The re-
chromatography of the collected monomer peak reproduced the gel-filtration profile both
in the presence and in the absence of tyrosine, indicating the dissociation is reversible
and not due to the protein damage during the chromatography process.
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In contrast to Δ155 TyrH, wild-type TyrH only slightly dissociates in the
presence of phenylalanine when the protein concentration is very low (Figure 4.5),
suggesting the existence of an inter-subunit binding region on the regulatory domain.
This is supported by the results of a previous study, in which TyrH became a monomer
after deletion of both the regulatory domain and C-terminal 20 amino acids (20),
suggesting that there is no strong interaction between adjacent catalytic domains. The
dimeric form of 54k TyrH is consistent with the existence of a dimerization region in the
regulatory domain.
The first ~70 amino acids were recently shown to be involved in the regulation of
TyrH (86, 108).  It is not likely that the dimerization site is before residue 70, because
these residues have high mobility and lack secondary structure (108). Consistent with
this, both Δ32 TyrH and Δ68 TyrH have a very small fraction of the tetramer dissociate
into monomer upon phenylalanine binding. This suggests that the main interactions
required for dimerization is between residues 68 and 155, and there is a minor
contribution before residue 68. Residues after 70 form an ACT domain, the function of
which is unknown in TyrH. ACT domains are generally the regulatory domains of amino
acid metabolizing enzymes, whose activity is modulated by the binding of amino acid to
the ACT domain (130, 131). The regulatory domain of PheH also contains an ACT
domain (28) that comprises the majority part of the regulatory domain. Although TyrH
and PheH share a low sequence similarity before the ACT domains (residues 1-24 of
PheH and 1-70 of TyrH), they share ~ 50% sequence similarity of the ACT domain and
> 70% sequence identity in the catalytic domain. With no structure of the regulatory
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domain of TyrH available, the structure of PheH (residues 25-452) could reflect that of
TyrH (residues 71 – 498). The structure of PheH containing residues 25-452 is obtained
by the alignment of the structures of two truncated PheH (one missing the first 117
residues and the other missing the last 25 residues).  As shown in Figure 4.8, the ACT
domains of neighboring subunits interact with both catalytic domains to form a dimer.
This suggests that the ACT domains help maintain the tertiary structure of TyrH.
Figure 4.8: The structure of PheH. The structure is obtained by aligning the structure of
PheH lacking first 117 residues (2PHM) and the structure of PheH lacking the last 25
residues (2PAH), followed by deleting the overlapping residues in 2PHM and residues
before position 25 in 2PAH. The regulatory domain is in red and the rest of the molecule
in gray. A: The tetrameric form of PheH shows that each regulatory domain is in contact
with two catalytic domains. B: Side view of the interaction between the regulatory
domain and the catalytic domain. Only two neighboring subunits are shown in B.
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The small peak between the tetramer and monomer peaks seen in the gel
filtration analysis of Δ155 TyrH suggests the dimer is not stable, with a strong tendency
to dissociate into monomers. That the tetramer of wild-type TyrH is formed by two
intermediate dimers was proposed in previously publication (27), based on the finding
that mutations disrupting the tetramerization domain yielded mostly dimer, but very little
monomer (27). The crystal structure of the catalytic domain of TyrH shows that the C-
terminal end of the catalytic domain contains an interaction between β-sheets of two
adjacent subunits (14), suggesting that the tetramer is formed by dimerization of two
dimers. The β-turn interaction is not strong enough to hold a dimer, because truncating
the N-terminal regulatory domain and the C-terminal tetramerization domain (but still
contains the β-turns) yields a monomer, rather than a dimer (26). Thus, the ACT domain
is responsible for keeping the intermediate dimers from dissociation. The absence of a
dimer of wild-type TyrH in gel-filtration chromatography suggests that the dimer of
wild-type TyrH exist only as an intermediate, which associates back to tetramer very
promptly. Further, because of the reinforcement of the dimerization between the
regulatory domain and the catalytic domain, the presence of tyrosine has minimal impact
on the tertiary structure of wild-type TyrH.
The binding of substrates for TyrH is sequential, with pterin binding first,
followed by molecular oxygen and then tyrosine (41), suggesting that tyrosine does not
bind to TyrH productively in the absence of the other two substrates. However, there is
an increase in deuterium incorporation in peptide 342-348 upon tyrosine binding in wild-
type TyrH and Δ155 TyrH, suggesting that a second binding site of tyrosine rather than
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the active site might be present and responsible the dissociation of Δ155 TyrH upon
tyrosine binding. Consistent with this, residues 342-348 is part of a helix far away from
the active site of TyrH and none of those residues have been shown to be critical for
TyrH activity.
In summary, we designate another function to the regulatory domain of TyrH,
which is dimerization to the catalytic domain of another subunit. We also locate this
dimerization region to residues 68 - 155 by deletion mutants. This dimerization may help
the protein to be more stable.
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CHAPTER V
SUMMARY
This study is aiming at identifying the structural changes related to regulation of
TyrH. TyrH catalyzes the hydroxylation of tyrosine into DOPA, the first and rate-
limiting step in the catecholamine biosynthetic pathway. TyrH is regulated by inhibition
through catecholamine binding or activation through Ser40 phosphorylation. The
inhibition by catecholamines is via tight binding of catecholamines with ferric protein,
while Ser40 phosphorylation activates the enzyme by facilitating catecholamines to
dissociate. Structural changes related to regulation of TyrH have been suggested, but not
located to specific regions.
To locate the structural changes related to regulation, hydrogen deuterium
exchange mass spectrometry (HDMS) was performed. Ser40 surrounding region
(residues 35-71) is identified as involved in the structural changes upon dopamine
binding, although this region is not identified after Ser40 phosphorylation. In addition, a
small peptide of the catalytic domain, 295-299, is also identified as involved in structural
changes upon regulation. Residues 35-71 and 295-299 show less deuterium
incorporation upon dopamine binding, whereas residues 295-299 have a slight increase
in deuterium incorporation upon Ser40 phosphorylation. Although peptide 35-71 is lost
in HDMS after Ser40 phosphorylation, results of limited proteolysis have showed that
residues 33-50 become more solvent accessible upon phosphorylation.  Thus, same
peptides are involved in structural changes upon dopamine binding and Ser40
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phosphorylation, and they undergo opposed structural changes in the two regulatory
mechanisms. Peptide 295-299 is part of a loop (288-298) at the active site entrance; the
other half of the loop, peptide 287-294, does not show difference in deuterium
incorporation upon regulation. This suggests that the changes in deuterium incorporation
of residues 295-299 upon regulation is not due to the movement of the loop, which
would have lead to similar changes in deuterium incorporation in residues 287-294.
Rather, it is likely that the primary conformational changes happen in peptide 35-71
upon regulation, which then causes the differences in solvent accessibility to peptide
295-299.
To further investigate the role of the regulatory domain in regulation of TyrH,
acrylamide fluorescent quenching and fluorescent anisotropy were performed on mutants
of TyrH containing a single tryptophan at positions 14, 34 or 74.  Compared with
limited-proteolysis, acrylamide fluorescent quenching could provide information on
solvent accessibility more quantitatively, which would complement the missing of
peptide 35-71 upon phosphorylation in HDMS. There is an increase in the solvent
accessibility at position 34 upon Ser40 phosphorylation, whereas the differences in
solvent accessibility at position 14 and 74 are smaller. Consistent with acrylamide
fluorescent quenching, there is a decrease in steady-state anisotropy and an increase in
dynamic anisotropy at position 34 upon Ser40 phosphorylation. The increase in dynamic
anisotropy directly show that phosphorylation increases the flexibility of position 34
containing peptide, agreeing with that the primary movement of this region is part of the
conformational changes during regulation.
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Because the structure of the regulatory domain of TyrH is not available, the
structure of the regulatory domain of PheH is used to explain the conformational
changes of TyrH upon regulation, which shifts the equilibrium between a closed
conformation and an open conformation. Upon a catecholamine binding, the N-terminus
of the regulatory domain covers over the active site and interacts with peptide 295-299,
shifting the equilibrium to the closed form. This prevents the dissociation of the
catecholamine from the active site, making the dissociation rate constant ~ 1nM. The
closed conformation also causes the N-terminus of the regulatory domain and peptide
295-299 less solvent accessible, making TyrH less susceptible to proteolysis or Ser40
phosphorylation. Upon Ser40 phosphorylation, the N-terminus of the regulatory domain
moves away from the active site and peptide 295-299, shifting the equilibrium toward an
open form. In the open form, the bound catecholamine could dissociate much easier,
increasing the dissociation rate constant of a catecholamine to ~ 1 µM. Because the N-
terminus of the regulatory domain is away from residues 295-299 in the open form, both
of the N-terminus and peptide 295-299 gain more solvent accessibility. The deletion of
the regulatory domain yields an enzyme with similar steady-state kinetic parameters to
the resting enzyme, indicating the regulatory domain does not restrict the substrate from
entering the active site. Thus the resting enzyme is more close to the open form, which is
also suggested by the small increase in solvent accessibility to peptide 295-299 upon
Ser40 phosphorylation.
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